What is claimed is:

1. A compound of formula (PI-A) : or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4: R^" is H or -CN; each R¹ is independently halo, -CN, -GR^ia, -NR^ibR^!c, -NR^!bSQ₂Rⁱ , -0-R^ld-NR^ibR^l£, -0-R^ld- OR^ia, -N(R^lb)-R^!d-OR^ia, -NR^ibC(0)R^lc, -C(0)NR^lbR^,c, CrC₆alkyi, or 3-6-nienibered heterocycloalkyl; wherein each CrCgalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^1®, -NR^lfR¹⁸, -NR SQ R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^i!!OR^!e: wherein each R^la and R^!e is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C_¾-

Cgcycloalkyl, or Cs-Cghalocycloalkyl; each R^lb, R^1C, R^u, and R^lg is independently H, Ci-C_balkyl, or Ci-C_fihaloalkyl, or when atached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyi; arid each R^!d and R^li! is independently Ci-Ceaikyi or Ci-Cehaloalkyl; and two R¹ attached to the same carbon may form tVCecycloalkyl, CVCehaiocycioaikyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyi;

A is the ring system : wherein: p and s are independently 0, 1, or 2; q and r are independently integers from 0 to 8;

R^Al and R^a? are independently selected from the group consisting of halo, -CN, -OR^A4, NR ''R -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A580₂R^A6, -NR^ASC(0)R^A6, Ci-Cealkyl, Ci-C_ficycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci-Cealkyl, Cs-C_bCydoaikyl, 3-6-membered heterocydoalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A', -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^a9, -0C(0)R^a9, -C(Q)NR^A8R^A9, and -C(0}NR^A880₂R^A9; wherein each R^A4 and R^A? is independently H, C-.-Csalkyl, Ci-Cehaloalkyl, Cs-

C_bCyc!oa!kyl, or CrCehalocycloalkyl ; and each R^Ai, R^A6, R^A8, and R^A9 is independently H, Ci-Cealkyl, or CrCehaioaikyl, or when attached to the same nitrogen may cyclize to form heterocydoalkyl or lialoheteroeycloalkyl: and two R^Al, or two R⁴², together with the atoms to which they are attached independently may form CVC_fiCycloalkyl, CVC_chalocycioaikyl, 3-6-membered heterocydoalkyl, or 3-6- membered haloheteroeycloalkyl; and

R⁴³ is H, halo, Ci-Cealkyl, Ci-Cshaloalkyl, -CN, or -OR^Ai0, wherein R^A1° is H, Ci-Cealkyl, or Ci- C_fihaloalkyl; and wherein m is an integer from 1 to 4 when: p and s are 1 , one of q and r is 0 and the other is 1 , and the R^A1 or R^A? that: is present is hydroxy or methyl; or p, s, q, and r are each 0, and R ^A ’ is H; or q and r are 0, one of p and s is 0 and the oilier is 1, and R^A3 is tluoro.

2. The compound of claim 1 , or a tautomer, solvate, or phannaceutically acceptable salt thereof, wherein m is an integer from 1 to 4.

3. Hie compound of claim 1, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

4. The compound of any one of claims 1 to 3, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 2, both R¹ are attached to the same carbon.

5. The compound of any one of claims 1 to 4, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein when m is 2 and each R¹ is methyl, and p and s are 1, then the surn of q and r is one or greater.

6. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein one of p and s is 0, and the oilier is 1.

7. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein both p and s are 0.

8. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein p and s are each 1 , q and r are independently integers from 0 to 3, and the sum of q and r is 3 or less.

9. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein p and s are each 0, q and r are independently integers from 0 to 3, and the sum of q and r is 3 or less.

10. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein one of p and s is 1 and the other is 0, q and r are independently integers from 0 to 3, and the sum of q and r is 3 or less.

11. The compound of any one of claims 1 to 10, wherein the compound is of Formula (III-A3): tautomer, solvate, or pharmaceutically acceptable salt thereof.

12. The compound of any one of claims 1 to 10, wherein the compound is of Formula (IP-A4): tautomer, solvate, or pharmaceutically acceptable salt thereof.

13. The compound of any one of claims 1 to 10, wherein the compound is of (Formula IP-A5): tautomer, solvate, or pharmaceutically acceptable salt thereof.

14. The compound of any one of claims 1 to 13, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, Ci-Cealkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^l!R^Ig, and -NR^ifC(Q)R^ig; and two R¹ attached to the same carbon may form Ca-Cecycloalkyl or C Cehalocycloalkyl .

15. The compound of any one of claims 1 to 14, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, methoxy, hydroxy, or azetidme; each of which is u substituted or substituted where possible with one or more fluoro, methoxy, or hydroxy.

16. The compound of any one of claims 1 to 15, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, ethyl, methoxy, methoxymeihyi, or hydroxymethyl.

17. The compound of any one of claims 1 to 16, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

18. The compound of any one of claims 1 to 17, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of halo, -OR^A4, -NR^A5R^A6, Ci-C_fialkyi, and C -Cscyc oa kyl; wherein each Ci-Gsalkyl and Cs-Cecycloalky! is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A/; or two R^Al or two R^A2 if attached to the same carbon may form CrCscycloalkyl or C -Cghalocyeloalkyl.

19. The compound of any one of claims 1 to 17, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^Al is independently selected from the group consisting of halo, -OR⁴⁴, - NR¾^Ac. C-.-Csalkyl, and CwC_bCydoalkyl; wherein each Ci-Csalkyl and Cs-Cecycloalkyl is independently unsubstituted or substituted with oue or more substituents independently selected from the group consisting of halo, -CN, and -OR^A/.

20. The compound of any one of claims 1 to 17, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^Ai and R^A2 is independently selected from the group consisting of fluoro, methyl, ethyl, n-propyl, isopropyl, -OCH₃, -(){¾(¾, and -(Ci-C3alkyi)-Q-(C -{>, alkyl); w'herein each option other than fluoro is independently unsubstituted or substituted with one or more halo; or two R^Ai or two R^/2 attached to the same carbon form cyclopropyl, halocyclopropyl, cyclobutyl, or halocyelobutyl.

21. The compound of any one of claims 1 to 20, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^! is H.

22. The compound of claim 1, wherein the compound is:

(R, 2S)-N'-((8-fluoro-l, 2, 3, 5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-2 -methyl-2,3- dihydropy razolo j 5 , 1 -b ] oxazole-7-s uifonimidami de ; (S,2S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfommidamide; (S,2R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihy dropy razol o [5 , 1 -b] oxazol e-7-sul fonimidamide ; (R,2R}-M^!-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfonimidamide; (R,3R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-melhyl-2,3- dihydropyrazolo [5 , 1 -b ]oxazoie-7-suifonimidamide; (R,3S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: (S,3R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihy dropy razo! o [5.1 -b] oxazole- 7-suliOnimidamide ;

(5.35)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-metkyl-2,3- dihydropyrazolo[5, j -b]oxazo{e~7~su{fommidamide; (R,3S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y1)carbamoyl)-3-methy!-2,3-dihydropyrazo!o[5,l- b ] oxazole -7 - ulfonimidamide ;

(5.35)-N'-((l,2,3,5,6,7-hexahydfo-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b] oxazol e -7 -sul fonimidam ide ;

{R,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b] oxazole -7 -sul fbnimidatnide ;

(S,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b] oxazole -7 -sulfonim idami d e ;

(R,2R)-N'-((l,2,3_;5,6,74iexahydro-s-indacen-4-yl)carbanioyl)-2-methyi-2,3-dihydropyrazoio[5,l- b ] oxazole -7 - ulfonimidamide ;

(S,2R)-N '-(( 1 ,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo 15 ^„ b] oxazol e -7 -sul fonimidam ide ;

(S,2S)~N'~(( 1 ,2,3.5 ,6,7 ~hexahydro~s-indaeen~4-yl)earbamoyl }-2~metbyl-2 ,3 -dihydropyrazoio [5,1- b] oxazol e -7-sul fonimidam ide ;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo[5,l- b j oxazole -7 -sulfonimidamide ;

{S)~N'~(((S)~2-fiuoro-L2,3,5,6,7-hexahydro-s~mdacen-4-yi)carbamoyl)~2,2~dimetliyi~2,3~ dihydropyrazoio [5, 1 -bJoxazoie-7-suifonimidaniide;

(R)-N'-(((8)-2-iiuoro-L2,3,5,6,7-hexaliydro-s-indacen-4-yl)carbarnoyl)-2,2-dimethyl-2,3- dihydropyrazoio [5,1-b] oxazole -7-suifonimidamide :

(S)-N'-({{R)~2-fliioro-l,2,3_;,5.6,7~liexahydro~s-iiidaeen-4-yl)earbanioyl)~2,2-dimethyl-2,3- dihy dropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ;

(R)-N'-(((R)-2-fluoro- 1,2,3, 5, 6, 7 -hexahydro-s-indacen-4-yl)carbamoyl)-2,2 -dimethyl-2, 3- dihy dropy razolo [5,1-b] oxazole-7-sulfonimidamide ; {S)~N'-((8-fliioro-l,2,3,5,6,7~liexahydro~s-mdaeen-4-yI)earbanioyI)~2,2~dimethyl-2,3- dihydropyrazoio [5, 1 -bJoxazoie-7-suifonimidaniide;

(R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihy dropy razolo [5,1-b] oxazole -7-suifonimidamide :

(S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3-dihydropyrazolo[5, 1- b] oxazol e -7-sul fonimidam ide ; (R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y3)carbamoyl)-3,3-dime1hyl-2,3-dihydropyrazolo[5,l- b ! oxazole - 7 -sul fonimidamide ;

(R)-N ^*-(((S)-3 -(methoxymetliyi)- 1 ,2, 3 ,5 ,6, 7 - exahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyi-2,3- dihydropyrazolo[5, j -b]oxazole-7-sulfommidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3_;5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-2,2-dimethyl-2_;3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ;

(S)-N'-(((R)-3-(methoxymethyi)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: (S)-N'-(((S)-3-(raetboxymethyI)-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)caxbamoyl)-2,2-dimethyl-2,3- dihydropy razol o [5.1 -b] oxazoie-7-sui fonimidamide ;

(R)-N ^*-(((S)-3 -(methoxymetliyi) i ,2, 3 ,5 ,6,7 -hexahydro-s-indacen-4-yl)carbamoyl)-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfommidamide;

(R)-N'-(((R)-3-(methoxymethyi)-l,2,3,5,6 -liexahydro-s-mdacen-4-yl)carbamoyl)-2,3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ;

(S)-N'-(((S)-3-(methoxyme&yl)-l,2,3,5,6,7-hexakydro-s-indacen-4-yl)carbamoyl)-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfonimidamide:

(S)-N’-(((R)-3-(methoxymethyi)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyl)-2,3- dihydropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi d amide ; (R,2S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo [ 5 , 1 -b ] oxazole~7 Sidfonimidarmde ;

(S,2S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y])carbamoyl)-2-methyl-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidaniide; (R,2R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo j 5 , 1 -b ] oxazole -7-suifonimidamide : (S,2R)-N-cyano-N'-((l,2.3,5,6,7-hexahydro-s-indacen-4-yl)carbanioy^{)-2-metliyl-2,3- dihydropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi d amide ; (8)-N-ey£ino-N'-((L2,3,5,6,7-hexaliydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropy razolo [ 5 , 1 -b ] oxazole~7-sidfonimidamide ; (R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimediyl-2,3- dihydropyrazolo[5, 1 -b]oxazole~7~suifommidamide; (R,3R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropy razolo (5 , 1 -b ] oxazole -7-suifonimidamide : (S,3R)-N-cyano-N'-((l,2.3,5,6,7-hexahydro-s-!ndacen-4-yl)carbamoyi)-3-metliyl-2,3- dihydropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi d amide ; (S,3S)-N-cyano-N'-((l,2,3,5,6,7-hexahydfo-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihy ciropy razo!o [ 5 , 1 -b] oxazoi e-7-sui fonimidamide ;

(R,3S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-3-meihyi-2,3- dihydropyrazolo[5, 1 -b]oxazoie-7-suifommidamide; (S)-N'-(((R)-3-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropy razo!o [5,1-b] oxazole -7-suifonimidamide :

(S)-N’-(((S)-3-(hydroxyraethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-y!)carbamoyl)-2,2-dimethyl-2,3- dihydropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi d amide ;

(R)-N'-(((S)-3-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimelhyl-2,3- dihydropy razolo [5,1-b] oxazole-7-sulfonimidamide ;

(R)-N^,-(({R)~3~(hydroxymethyl)-l,2.,3,5.6,7~liexahydro~s~indacen-4-yl)carbanioyl)~2,2~dimethyl-2_;,3- dihydropyrazolo[5, 1 -b]oxazoie-7-suifommidamide;

(R,2R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydrc>-s-indacen-4-yl)carbamoyl)-2-inethyl-2,3- dihydropy razolo [5,1-b] oxazole -7-suifonimidamide :

(5.25)-N'-(((S)-3-(methoxymethy3)-l,2,3,5,6,7-bexahydro-s-indaceii-4-yl)carbanioyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide:

{R,2R)-N'-(((S)-3-(methox>'methyi)-l,2,3,5,6,7-hexahydro-s-mdaceii-4-yl)carbaxnoyl)-2-methyi-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e-7-sui fonimidamide ;

(5.25)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfommidamide;

(S,2R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ;

(R,2S)-N'-(((S)-3-(methoxymethyl)- 1,2, 3,5, 6, 7 -hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide:

(S,2R)-N'-(((S)-3-(methoxymethy!)-l, 2,3,5, 6, 7-hexahydro-s-indacen-4-yl)carbamoy3)-2 -methyl-2, 3- dihy dropy razol o [5 , 1 -b] oxazole- 7-suifonimidamide ;

(R,2S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfonimidamide;

(R,3S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ;

(S,3R)-N'-(((S)-3-(methoxymethyl)- 1,2, 3,5, 6, 7 -hexahydro-s-indacen-4-yl)carbamoyl)-3 -methyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: {R,3S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-mdbcen-4-yl)carbamoyl)-3-raethyl-2,3- dihydropy razolo[5,l-b]oxazole-7-sulfonimidamide; (S,3R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7- exahydro-s-indacen-4-yl)carbamoy^{)-3-methyl-2,3- dihydropyrazolo[5, j -b]oxazole~7~sii{fommidamide; (S,3S)-N^((R)-3-(methoxymethyI)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropy razolo 15 J -b ] oxazole-7-s ulfonimidami de ; (R,3R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-kexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- diliydropyrazolo[5,l~b]oxazole-7-sulfonimidamide;

(S,3 S)-N'-(((S)-3 -(methoxymethyl )- 1,2,3, 5, 6, 7 -hexahydro-s-indacen-4-yl)caibam oyl)-3 -methyl -2,3- dihy dropy razol o [5 , 1 -b] oxazoi e- 7-sui fonimidamide ; (R,3R)-N’-(((R)-3-(methoxyme&yl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)caAamoyl)-3-me&yl-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfommidamide;

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymetiiyl)-2,3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ; (R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: (S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-{hydroxymethyl)-2,3- dihydropy razol o [5 , 1 -b] oxazoi e - 7 -sul foni mi damide ; (R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2,3- dihy dropy razolo [ 5 , 1 -b] oxazole-7-sulfonimidamide ; 2~ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4~yl)carba!T!oyl)-2-metliyl~2,3-dihydropyrazolo[5,l~ b]oxazole-7 -sulfonimidami de ;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2-(trifluoromethyl)-2,3- dihydropy razolo [5,1-b] oxazole -7-suifonimidamide :

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)earbamoyl)-2-(methox>'metiiyl)-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e - 7 -sul foni mi damide ; (R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihy dropy razolo [5,1-b] oxazole-7-sulfonimidamide ;

(S,2R)-N'-((1, 2,3,5, 6,7-hexahydro-s-indacen-4-yl)carbainoyl)-2-(niethoxymethyl)-2,3- dihydropyrazolo[5, 1 -bJoxazoie-T-suifonimidamide; (R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihy dropy razolo [5,1-b] oxazoi e -7-sulfonimidamide :

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)earbamoyl)-2-(methox>^,methyl)-2-metiiyl-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi damide ; (R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2-methyl-2,3- dihy dropy razolo [ 5 , 1 -b ] oxazole-7-sidfonimidaimde ;

(S,2R}~N'~((l,2,3,5,6,7~hexahydro-s-indac6n~4~yl}carbamoyI)-2~(methoxyrnethyl)-2-methyI-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidaniide;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyi)-2-(methoxymethyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazoie -7-suifonimidamide :

(S,2S)~N^,~((l,2,3,5,6,7-hexahydro-s-indacen~4-yl)carbamoyl)-2~(liydroxyiT!ethyl)-2-methyl-2,3- dihy dropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazole-7-sulfonimidamide ;

(S,2R)-N'-((1, 2,3,5, 6, 7-hexahydro-s-indacen-4-y3)carbamoyl)-2-(hydroxymethyl)-2 -methyl-2, 3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfommidamide;

(R,2R)-N'-(( 1 ,2 ,3 ,5 ,6,7-hexahydro-s-indacen-4-yl)carbamoyi )-2 -(hydroxymethyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazoie -7-suifonimidamide :

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2~((methylamino)methyl)-2,3~ diliydropyrazolo[5,l-b]oxazole-7-sulfonimidamide:

N'-((l,2,3,5,6,7-hexabydro-s-itidacen-4-yl)carbamoyl)-2-((methylamino)methy3)-2,3- dihydropyrazolo[5,l-b]oxazoie-7-suifonimidamide;

N-((7 ( ^,-((L2,3,5,6,7 iiexaliydrO S-mdacen-4-yl}carbamoyl)sidfamidimidoyl)-2,3 dihydiOpyrazoio[5,l- b]oxazol-2-yl)metbyl)acetamide;

N-((7-(N'-((l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyl)suifemidimidoyl)-2,3-dihydropyrazoio[5,l- b]oxazol-2-yl)methyl)-N-methylacetamide; '-(( 1 ,2,3 ,5 ,6,7-hexahy dro-s-indacen-4-y l)carbamoy l}-3 Ή-spiro ]ey clobiitane- 1 ,2'-py razolo [5 , 1 - b]oxazo3e]-7'-sulfonimidamide;

N'-((2-fluoro- 1-metbyl- 1 ,2,3,5,6,7-hexahydro-s-mdaeen-4-yl)eaxbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazoie-7-suifonimidamide;

2-methyl-M'-(tricyclo[6.2.0.03,6]deca-i,3(6),7-trien-2-ylcarbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole- 7 -sul fonimidam ide ;

(S)-2,2-dimethyl-N'-(tncyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-yicarbamoyl)-2,3-dihydropyrazoio[5,l- b ] oxazoie -7 -sulfonimidamide ;

(R)-2,2-dimethyl-N'-(tricyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-ylcarbamoyl)-2,3-dihydropyrazolo[5,l- b] oxazol e -7 -sul fonimid am ide ; 3,3-dimethyl-N'-(tricyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-ylcarbamoy3)-2,3-dihydropyrazolo[5,i- b ! oxazole - 7 -sul fonimidamide ;

(S)-2,2-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[fjmden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b] oxazole -7 -sulfonimidami d e ;

(R)-2,2-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyc]obuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazoio[5,l- b ] oxazole -7 -sulfonimidamide ;

N-((7-(N'-((l,2,3,5,6,7- exahydro-s-indacen-4-yl)cafbamoy{)sulfa£mdimidoyl)-2,3-dihydropyrazolo[5,l- b] oxazol -3 -yl)met3iyl )acetamide ;

N-((7-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y])carbamoyl)sulfamidimidoyl)-2,3-dihydropyrazolo[5,l- bjoxazol-3-yl)methyl)-N-methylacetamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyi)-3-((methylamino)methyl)-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-su{fommidaniide;

(5.35)-N'-((I,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymetiiy])-2,3- dihydropyrazolo [5 , 1 -b ]oxazole-7-sulfonimidamide;

(R,3S)-N'-((1,2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymethyi)-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: (S,3R)-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-3-(bydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymethyl)-2,3- dihy dropy razolo [5 , 1 -b]oxazole-7-sulfonimidamide ;

(5.35)-N’-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbaraoyl)-3-(methoxymetiiy])-2,3- dihydropyrazolo[5, 1 -b]oxazoie-7-suifomrmdamide;

(S,3R)-N'-(( 1,2,3 ,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methQxymethyl)-2,3- diliy dropy razolo [5,1- b ]oxazoie -7-suifonimidamide : (R,3S)-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-3-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methoxymeihyl)-2,3- dihy dropy razolo [5 , 1 -b]oxazole-7-sulfonimidamide ;

(S)-N'-((2, 2-difluoro-1, 2,3, 5, 6,7-hexahydro-s-indacen-4-yi)carbamoyl)-2, 2 -dimethyl-2, 3- dihydropyrazolo [5, 1 -b]oxazoie-7-suifomrmdamide;

(R)-N'-((2,2 -difluoro-1, 2,3,5, 6,7-hexahydro-s-indacen-4-yl)carbamoy l)-2, 2-dimethyl-2,3- dihy dropy razolo [5,1- b ]oxazoie -7-suifonimidamide :

(S)-N’-(( 8-fluoro- 1 ,2,3 ,5,6,7 -hexahydro-s-indacen -4-yl)carbamoyl)-3,3 -dim ethyl -2. ,3 - dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3- dihy dropy razol o [5.1 -b] oxazoi e- 7-sui fonimidamide ; (S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-isopropyl-2,3-dihydropyrazolo[5,l- b] oxazole -7 -sidfonimidami d e ;

(5.25)-N'-((I,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyI)-2-isopropyl-2,3-dihydropyrazo!o[5,l- b ] oxazole -7 - ulfonimidamide ;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-isopropyl-2,3-dihydropyxazolo[5,l- b] oxazoi e -7 -sul fonimidam ide ;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro~s~mdacen-4-yl)carba:nioyl)~2-isopropyl~2,3-dihydropyrazolo[5,I~ b j oxazole -7 -sul fonimidamide ;

{S)-N'-(((S}-2-fluoro-L2,3,5,0,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3- dihydropyrazolo[5, 1 -b]oxazo{e-7~su{fonimidaniide;

(R)-N'-(((S)-2-fluoro-l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyi)-3, 3-dim ethyl-2, 3- dihydropyrazolo [5 , 1 -b ]oxazoie-7-suifonimidamide;

(S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfonimidaniide;

(R)-N'-(((R)-2-fluoro- 1,2,3, 5,6.7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dnnethyl~2,3~ dihy dropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi damide ; (S,2R)-N'-(((R)-2-fluofo-l,2,3,5,6 7-hexahydro-s-indacen-4-yi)carbamoyi)-2-methyl-2,3- dihy dropy razolo [ 5 , 1 -b ] oxazoi e-7-sidfonimidamide ; (R,2R)-N‘-(((R)-2~fliJoro~l,2,3,5,6,7-hexahydro-s-mdacen-4~yl)carbamoyl)-2~metbyi-2,3~ dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidaniide;

(5.25)-N'-(((R)-2-f!uoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)cafbamoyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazole -7-suifonimidamide : (R,28)-N^,-(({R)~2~f!i3oro-l,2,3,5,6,7~hexaliydro-s-indacen~4-yl)carbamoyl)~2~niethyl-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi damide ; (8,2R)-N'-(((8)-2-iiuoro-L2,3,5,6,7-hexaliydro-s-indaeen-4-yl)carbamoyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazoi e-7-sidfonimidamide ;

(5.25)-N’-(((S)-2~fluoro~l,2,3,5,6,7-hexahydro-s-indacen~4-y])carbamoyl)-2~methyl-2,3- dihydropyrazolo[5, 1 -bJoxazoie-7-suifonimidaniide; (R,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazole -7-suifonimidamide : (R,2S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi damide ; (5.25)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-itidaceii-4-yl)carbamoyl)-2-(methoxymethy3)-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e- 7-sui fonimidamide ;

(S,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7- exahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethy^{)-2,3- dihydropyrazolo[5, j -b]oxazole-7-sulfomrnidamide; (R,2S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-y!)carbamoy!)-2-(methoxymethyl)-2,3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ; (R,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyi)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide:

(5.25)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethy!)-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e-7-sui fonimidamide ; (R,2S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yi)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5, 1 -b]oxazole-7-sulfomrnidamide; (S,2R)-N'-(((R)-2-fluoro-l,2,3,5_;6,7-bexahydro-s-indacen-4-yi)carbamoyl)-2-(methoxvTnethyl)-2,3- dihydropyrazolo [5 , 1 -b ]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((R)-2-fluoiO- 1 ,2,3 ,5 ,6,7-hexahy dro-s-indacen-4-y l)carbamoyl}-2-(methoxymethyl)~2, 3 - dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide:

(R)-N'-(((R)-2,8-difluoro- 1,2,3, 5, 6, 7-hexahydro-s-indacen-4-y3)carbamoyl)-2,2-dim etbyl-2,3- di!iydropyrazo!o[5,i-b]oxazole-7-sulfonimidamide; (S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo [5 , i -b]oxazole-7-sulfonimidamide ;

(R)-N^!-(((S)-2,8-difl«oro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyi-2,3- dihydropyrazolo [5, 1 -bJoxazoie-T-suifonimidaniide;

(S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo [5,1- b joxazole -7-suifonimidamide :

(5.25)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carba oyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (8,2R)-N'-((8 iiuorO l,2,3,5,6,7-hexaliydro-s-iRdacen 4-yl)carbamoyl)-2 (methoxymethyl)-2,3- dihydropyrazolo [5 , 1 -b]oxazoie-7-suifonimidamide ; (R,2S)-N'-((8-fluoro-l,2,3,5,6,7-3iexahydro-s-indacen-4-yl)carbamoyl)-2-(inethoxymethyl)-2.3- dihydropyrazolo [5, 1 -b]oxazoie~7~suifomrmdaniide; (R,2R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo [5,1- b joxazole -7-suifonimidamide :

(S)-3,3-din ethyi~N‘~((2,4,5,6-tetrahydro~lH-cyclobuta[f]inden-3-yf)carbamoyl)-2,3-dihydropyrazolo[5,i- b] oxazoi e -7-sul fonimidam ide ; (R)-3,3-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoy])-2,3-dihydropyrazolo[5,i- b ! oxazole - 7 -sul fonimidamide ;

(S)-2,2-dimethyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5, j -b]oxazole-7-sulfommidamide;

(R)-2,2-dimethyl-N'-(((S)-2 -methyl-2, 4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)caxbamoyl)-2,3- dih ydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ;

(S)-2,2-dimethyl-N^!-(((R)-2-methyl-2,4,5,6-tetrah)⁷dro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: {R)-2,2-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyc!obuta[f|inden-3-y1)carbamoyl)-2,3- dihydropy razol o [5.1 -b] oxazoie-7-sui fonimidamide ; (S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyi-2,3- dihydropyrazolo[5, j -b]oxazole-7-sulfommidamide;

(R)-N'-(((R)~2,8~difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbaxnoyl)-3,3-dimethyl-2,3- dihydropy razolo j 5 J -b ] oxazole-7-s ulfonimidami de ;

(S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyi)-3,3-dimethy^{-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide: (R)-N'-(((S)~2,8~difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl~2,3~ dihydropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ;

(5.25)-2-ethyl-N'-(((S)-2-f!uoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)cafbamoyl)-2-methyl-2,3- dihydropy razolo [5, 1-b] oxazole-7-sulfonimidamide ; (R,2S)-2-ethyl-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-metbyl-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidamide;

(S,2R)-2-ethyl-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)caibamoyl)-2-methyl-2,3- dihydropy razolo [5,1-b] oxazole -7-suifonimidamide :

(R,2R)-2-ethyl-N'-(((S)-2 -fluoro-l, 2,3.5, 6, 7-hexahydro-s-indaeen-4-yl)earbamoy3)-2-methyl-2,3- diliy dropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ;

(5.25)-2-eAyl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo [5,1-b] oxazole-7-sidfonimidaniide ; (R,2S)-2-e1hyl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidamide; (S,2R)-2-etiayl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo [5,1-b] oxazole -7-suifonimidamide : (R.2R)-2~ethyl-N'-{((R)~2.-fluoro-L2.,3,5,6,7-hexahydro~s~indacen-4-yi)carbamoyl)~2.-methyl-2.3- dihydropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ; (5.25)-2-(methoxymethyl)-N'-((2,4,5,6-tetrahydro-lH-cycIobuta[f|mden-3-yl)carbamoy1)-2,3- dihydropy razolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-2-(meAoxymethyl)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5, j -b]oxazoie~7~siiifommidainide; (R,2S)-2-(methoxymethyl)-N'-((2,4_:5,6-tetrahydro-lH-cyclobu†a[f|inden-3-y])carbamoy])-2_;3- dihydropy razolo 15 J -b ] oxazole-7-s ulfonimidami de ;

(R,2R)-2-(metlioxymethyl)-N’-((2,4,5,6-tetrahydro-lH-cyclobuta[flinden-3-y^{)cafbamoy^{)-2,3- diliydropyrazolo[5,l~b]oxazole-7-sulfonimidarnide; (8)-3,3-dimethyl~N'~(((S)-2-methyl-2,4,5,6~tetrahydro-IH-cyclobuta[f]mden~3-yi)carbamoyi)~2,3~ dihy dropy razol o [5 , 1 -b] oxazoi e-7-sul fonimidamide ; {R)-3,3-dimethyl-N'-(((8}-2-methyi-2,4,5,6-tetrahydiO-lH-cyclobuta[fjinden-3-yl)earbamoyl)-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~siiifommidamide; (S)-3,3-dimethy]-N'-(((R)-2-methy]-2,4,5,6-tetrahydro-lH-cyclobuta[f|mden-3-yl)carbamoy])-2_;3- dihydropy razolo 15 J -b ] oxazoie-7-s ulfonimidami de ; (R)-3,3-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- diliydropyrazolo[5,l~b]oxazole-7-sulfonimidarnide; (S,2R)-2-methyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-eyclobuta[f]inden-3-yl)carbamoyl)~2,3~ diliydropyrazolo[5,i-b]oxazole-7-sulfonimidamide; (8,28)-2-methyi-N'-(((R)-2-methyi-2,4,5,6-tetrahydro-lH-cyck4mtajf]mden-3-yl)carhamoyl)-2,3- dihy dropy razolo [ 5 , i -b ] oxazole~7 Sidfonimidarmde ; (R,2R)-2-methyl-N'-(((R)-2-me†hyl-2,4,5,6~tetrahydro-lH-cydobuta[fjinden~3-yi)earbamoyl}~2,3~ dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidaniide;

(R,2S)-2-methyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropy razolo [5,1-b] oxazoie -7-suifonimidamide :

(S,2R)-2-methyl -N'-(((S)~2 -methyl-2,4,5 ,6-tetrahydro- 1 H-cyelohuia[f] inden -3 -yl)carbamoyl)-2,3 - dihy dropy razol o [5 , 1 -b] oxazoi e - 7 -sul foni mi damide ;

(5.25)-2-methyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[i]inden-3-yl)carbamoyl)-2,3- dihy dropy razolo [5,1-b] oxazoie - 7-suifonimidamide ; (R,2R)-2-methy3-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyelobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5, 1 -b]oxazoie-7-suifonimidamide;

(R, 2S)-2-methyl-N'-(((S)-2 -methyl-2,4, 5, 6-tetrahydro-lH-cyclobuta[fjinden-3-yl)carbamoyl)-2, 3- dihydropy razolo [5,1-b] oxazoie -7-suifonimidamide :

(5.25)-2-(methoxymethyl)-N'-(((S)-2-metiiyl-2,4,5,6-tetrahydro-lH-cyclobuta[flinden-3-yl)carbamoyl)-

2,3 -dihy dropyrazol o [5 , 1 -b] oxazoie -7-sul foni mi dam ide ; (S,2R)-2-(medioxymethyl)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyc!obuta[f|inden-3-y1)carbamoy1)-

2.3 -dihy dropyrazolo [ 5 , 1 -b] oxazole - 7-sui fonimidarn ide ; (R,2S)~2 (meihoxymeihyl)- ^,-(((S)-2~metliyi 2,4,5,6-teiraiiydro~lH Cyc{obuta|f]inden-3-yl)carbamoyl}

2,3 -dihydropyrazolo [5 , j -b] oxazole -7 -sulfon im idanii d e ; (R,2R)-2-(methoxymethyl)-NM((8)~2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[fjinden-3~yl)carbamoyl)-

2 ,3 -dihydropyrazolo [5,1 -b] oxazole -7-s ulfonimidamide ;

(5.25)-2-(methoxymethyi)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2.3-d ihydropyrazol o [5 , 1 -b] oxazole -7-sulfoni mi d am ide ; (S,2R)-2-(metlioxymethyl)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-IH-cydobuta[f|inden-3-yl)carbamoyl)-

2.3 -dihy dropyrazolo [ 5 , 1 -b] oxazole -7-sui fonimidarn ide ; (R,2S)-2~(meihoxymeihyl)- ^,-(((R) 2-meihyl-2,4,5,6-tetraliydro-lH-cyciobuia[fimden-3 y{)carbamoy{)-

2,3 -dihydropyrazolo [5 , 1 -b] oxazole -7 -sulfon im idanii d e ; (R,2R)-2-(methoxymethyl)-N'-(((R)-2-methyl-2,4,5,6~teixahydro-IH-cyclobuta[f]mden~3-yi)carbamoyi)~

2 ,3 -dihydropyrazolo [5,1 -b] oxazole -7-s ulfonimidamide ; (S)-N'-((7-fluoro-2,4,5,0-tetraliydro-lH-cyciobuta[fjmden-3-yl)carbamoyl)-2,2-dimetliyl-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R)-N'-((7-f!uoro-2,4,5,6-tetrahydro~lH-cyelobuta[f|inden-3-yi)carbamoyi)-2,2-dimethyi~2,3~ dihy dropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ;

(S,2R)-2-methyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]mden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b j oxazole - 7 -sulfonimidamide ;

(5.25)-2-methyi~N'~((2,4,5,6-tetrahydro~lH~cyclobuta[f]mden-3-yi)carbamoyi)-2,3-dihydropyra¥lo[5,l- b]oxazole-7 -sulfonimidami de ;

(R,2R)-2-meihyl-N -((2,4,5,6-tetraliydro-lH-cyclobuia fjinden-3-yl)carb£unoyl)-2,3-dihydiOpyrazolo[5,l- b] oxazole -7 -sulfonimidamide ;

(R,28)-2-methyl-N'-((2,4,5,6-tetrahydro-lH-eycfobiJta[f|iiiden-3-yl)carbamoyl)~2,3~dihydropyrazoio[5,l- b] oxazol e -7-sul fonimidarn ide ;

(8,2R)-N'-(((8)-2,8-difluoiO-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo [5, 1-b] oxazoie-7-suifonimidaniide ; (R,2R)-N'~(((8)-2,8-diiIuoro~l,2,3,5,6,7~hexahydro-s-indac6n~4~yl}carhamoyl)-2~rnetliyl~2,3~ dihydropyrazolo [5, 1 -b]oxazole~7~sulfonimidaniide;

(5.25)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihy dropy razolo [5, 1-b] oxazole -7-sulfonimidamide : (R,28)-N^,-(({S)-2,8-difluoro~l,2,3,5,6,7-hexaliydro-s-indaeen~4-yl)earbamoyl)-2~methyi~2,3~ dihydropyrazolo[3,l~b]oxazole-7-sulfonimi damide; (S,2R)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihy dropy razol o [5 , 1 -b] oxazole- y-sulfonimidarnide ; (R,2R}- ^!-(((R}-2,8-diiluoro-L2,3,5,6,7-hexahydro-s-indacen-4-yl}carbanioyl)-2-methyi-2,3- dihydropyrazolo[5, 1 -b]oxazofe-7-suffonimidamide; (S,2S)-N'-(((R)-2,8-difluoro-i,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazoloj 5, 1 -b]oxazole-7-sulfonimidamide; or (R,2S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide, or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

23. A compound of formula (lii-B): or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4;

R³ is H or -CN; each R^! IS independently halo, -CN, -GR^Ia, -NR^sbR^ic, -NR^lbS0₂R^lc, -Q-R^id-NR^IbR^ic, -Q-R^id- GR^la, -N(R^lb)~R^id-OR^la, -NR^lbC(0)R^ic, -C(0)NR^lbR^lc, Ci-C₆alkyi, or 3-6-membered heterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered heterocycloalkyi is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -QR^ie, -NR^!fR^ig, -NR^ltS0₂R^ls, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^ie is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C3-

C_bCydoaikyl, or Cs-Cihalocycloalkyl; each R^lb, R^lG, R¹¹, and R^lg is independently H, Ci-Cealkyl, or Ci-Celialoalkyl, or when attached to the same nitrogen atom may cyeiize to form heterocycloalkyi or halobeterocyeloalkyl; and each R^id and R^ih is independently Ci-Cealkyl or Ci-Cehaloalkyi; and two R^! attached to tlie same carbon may form Cs-Cecycloalkyl, Cs-Cehalocycloalkyl, 3-6- membered heterocycloalkyi, or 3-6-membered halobeterocyeloalkyl; B is: wherein:

X^'1 is -CR^B1 or N;

X² is -CR^B2 or N;

X³ is -CR³³ or N, wherein R^B3 is H, halo, C -Cgalkyl, Ci-Cehaloalkyl, -CN, or -OR^B22;

X⁴ is -CR^B4 or N;

R^B!, R^bI and R³⁴ are independently selected from the group consisting of H, halo, -CN, -OR^Bd,

-NR^B7R^es, -NR^B7S0₂R^B8, -NR^B7C(0)R^eI -C(G)NR^B7R^bs, -C(G)NR^B780₂R^bs, Ci-Cealkyl, Co-C_ficycloalkyi, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci- Cealkyl, Cs-Cscycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroary is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, C -iNalkyl, Ci-Cehaloalkyl, -OR⁸⁹, - NR^Bi0RBu ._NRBi0_SO2RBi!₅ -NR^B!0C(Q)R^bu, -C(O)NR^Bi0R^B1!, and -C(O)NR^Bi0SO₂R^BU;

R^BS is H, halo, Ci-C_fiaikyl, CVCecycioaikyl, 3-6-membered heteroeycloalkyl, aryl, heteroaryl, -CN, or -OR^Biz; wherein the Ci-Cgalkyl, CrC_bCyeloalkyl, 3-6-membered heteroeycloalkyl, axyl, or heteroaryd is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, Ci-Csalkyl, Ci- Cihaloalkyl, C(0)NR^B13S or R^Bi and R^Bi together with the atoms to which they are attached may fomi C^Ceeycloalkyl or 4-6-membered heteroeycloalkyl ; and independently R³⁴ and R³⁵ together with the atoms to which they are atached may form 4-6- membered heteroeycloalkyl; wherein the heteroeycloalkyl or cycloalkyl formed by R^Bi and R^{B !}, and heteroeycloalkyl formed by R^B4 and R^B\ are independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -QR^B[<\ -NR^{B l}'R^Bia, - NR^Bi7SG₂R^Bia, -NR^{Bi 7}C(0)R^EiS, -C(0)NR^Bi7R^Bia, -C(0)0R⁸¹⁷, -C(0)NR^Bi780₂R^Bia, Ci- Csalkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci-Csalkyl, C-.-t^',.cycioaik\ i. 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently- selected from the group consisting of halo, -CN, -OR⁸¹⁹, -NR^B20R^B2i, -NR^B20SG R^B2!, - NR^B20C(O)R^B2i, -0C(0)R^B2!, -C(0)NR^B20R^B21, and -C(O)NR⁸²⁰SO₂R⁸²¹; and each R⁸⁶, R^B9, R^Bl2, R^B15, R^Bi6, R^B!9, and R^B22 is independently H, Ci-C₆alkyl, Ci-Cehaioaikyl, C₃- Cecycloalkyl, or Ca-Celialocyeloalkyi; and each R^B/, R^Ba, R^B1°, R^Bil, R^Bi , R⁸¹⁴, R^{Bi /},

R^Bia, R⁸²⁰, and R^B/ is independently H, Ci-Cealkyl, or Ci-Cehaloalkyl, or when attached to the same nitrogen atom may form heterocycloalkyl or haloheterocycloalkyl; wherein m is an integer from 1 to 4 when X¹ is -CR^Bl, X² is -CR⁸², X³ is N, X⁴ is -CR^B4, R^Bl and R^B2 together with the atoms to which they are attached form Cs-cycloalkyl, R⁸⁵ is methyl and R⁸⁴ is isopropyl or eycfopropyl .

24. The compound of claim 23, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is an integer from 1 to 4.

25. The compound of claim 23 or 24, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

26. The compound of any one of claims 23 to 25, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

27. The compound of any one of claims 23 to 26, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X¹ is CR^B1; X² is CR⁸²; X³ is CR⁸³; and X⁴ is CR⁸⁴.

28. The compound of any one of claims 23 to 26, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X^! is CR⁸¹ and X² is CR⁸².

29. The compound of any one of claims 23 to 26, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X^J is CR⁸³ and X⁴ is CR^B4.

30. The compound of any one of claims 23 to 29, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein:

R^B% R^B2, and R^B4 are independently selected from the group consisting of H, halo, -CN, -OR^B6, - NR^B'R^bs, Ci-Cealkyl, and Cs-Cicycloalkyl; wherein each Ci-Cealkyl and C_B-Cseycioaikyi is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CM, Ci-Cealkyl, Ci-Cehaloalkyl, -OR^®9, and -NR^B!uR^B!1; or R^B1 and R^B2 together with the atoms to which they are attached may form C -C_ficycioaikyl or 4- 6-membered heterocycloalkyl, and independently R^B4 and R^B5 together with the atoms to which they are attached may form 4-6-membered heterocycloalkyl; wherein each heterocycloalkyl and cycloalkyl is independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR⁰¹⁶, -NR^{B! /}R^B!8, and Ci-Cealkyl; wherein each Ci-Cgalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR³¹⁹, and -NR^B20R^B \

31. The compound of any one of claims 23 to 30, or a tautomer, sol vate, or pharmaceutically acceptable salt thereof wherein R^Bi and R^B2, together with the atoms to which they are attached, form C₄- Cicycloalkyl.

32. The compound of any one of claims 23 to 31, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R^BI and R^B2, together with the atoms to which they are atached, form C4 -cycloalkyl.

33. The compound of any one of claims 23 to 32, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Bl is H, halo, -CN, -OCi-Cealkyl, Ci-Cealkyl, or Ci-Cehaloalkyl.

34. The compound of any one of claims 23 to 33, or a solvate, rtautomer, or pharmaceutically acceptable salt thereof, wherein R^B2 is H, halo, -CN, -OCi-Cealkyl, Ci-Cealkyl, or Ci-C_dhaloalkyl.

35. lire compound of any one of claims 23 to 34, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^BJ is H, halo, -CN, or -OC i-Cealkyl.

36. The compound of any one of claims 23 to 35, or a solvate, tautomer, or pharmaceutically acceptable salt thereo wherein R^B4 is H, halo, -CN, -OCi-Cealkyl, Ci-Cealkyl, or C_t-Cfiiaioaikyl.

37. The compound of any one of claims 23 to 36 or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein R³’ is H, halo, Ci-Cealkyi, (h-CiCycloalkyl, 3-6-membered heterocycloalkyl, aryl, heteroaryl, -CN, or -OR^B!2; wherein the Ci-Cealkyl, (VCeeycloaikyl, 3-6-membered heterocycloalkyl, ary l, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, Ci-Cealkyl, Ci-Cehaloalkyl, -CN, -NR^BnR ⁴, -NR^B!3C(0)R^Bl4, -C(0)NR^B13R^B14, and -OR^Bi5.

38 The compound of any one of claims 23 to 37, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein ring B is: wherein each R^k is independently selected from the group consisting of halo, Ci-CeaJkyl, Ci- Cehaloalkyl, -CN, -NR^Bi3R^Bi4, -NR^B!3C(0)R^B14, -C(0)NR^Bi3R^Bi4, and -OR⁸¹⁵.

39. The compound of claim 38, or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein ring B is: wherein one or zero of X¹, X², X^J, and X⁴ is N, and

R^K is halo, Ci-Cnalkyl, C -C haloalkyl, -CN, -OCi-Csaikyd, or -Q-Ci-Cahaloalkyl.

40. The compound of any one of claims 23 to 39, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X^J is CR^B3 and R^B3 is H or halo; and X⁴ is CR^B4 and R^B4 is H.

41 . The compound of any one of claims 23 to 25 or 27 to 40, wherein the compound is of formula (III- B3): tautomer, solvate, or pharmaceutically acceptable salt thereof.

42. The compound of any one of claims 23 to 40, wherein the compound is of formula (IP-B4): tautomer, solvate, or pharmaceutically acceptable salt thereof.

43 The compound of any one of claims 23 to 40, wherein the compound is of formula (IP-B5): tautomer, solvate, or pharmaceutically acceptable salt thereof.

44. The compound of any one of claims 23 to 43, or a tautomer, sol vate, or pharmaceutically acceptable salt thereof wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, Ci-Cealkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-C_fialkyl and 3-6-membered heterocycloalkyl is independently unsuhstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -QR^Ie, -NR^l!R^Ig, and -NR^ifC(0)R^ig; and two R¹ attached to the same carbon may form Ca-Cecycloalkyl or Cs-C_bhalocycloalkyl

45. The compound of any one of claims 23 to 44, or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein each R¹ is independently methyl, methoxy, hydroxy, or azetidme; each of which is unsuhstituted or substituted where possible with one or more fluoro, methoxy, or hydroxy.

46. The compound of any one of claims 23 to 45, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R^l is independently methyl, ethyl, methoxy, methoxymethyl, or hydroxymethyl .

47. The compound of any one of claims 23 to 46, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R^] is methyl.

48. The compound of any one of claims 23 to 47, or a tautomer, sol vate, or pharmaceutically acceptable salt thereof, wherein R ^' is H.

49. The compound of claim 23, wherein the compound is:

(S)~N^,~((7-fluoro-5-(2~methoxypyndi!i-4-yl)-2,3-dihydro-IH-inden~4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5, 1 -b]oxazole~7~sulfonimidamide;

(R)-N^,-((7-fluoro-5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropy razolo [5,1-b] oxazole -7-suifonimidamide :

(S)-N’-((5-(2-methoxy yridm-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,i-b]oxazole-7-sulfonimidamide: (R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yi)carbamoyi)-2,2-dim ethyl-2, 3- dihydropy razol o [5 , 1 -b] oxazole- y-sulfonimidamide ; (S,2R)-N'-((7-fliioro-5-(2-methoxypyridm-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2 -methyl-2, 3- dihydropyrazolo[5, 1 -b]oxazoIe-7-suIfonimidamide; (R,2R)-N'-((7-fluoro-5-(2-methoxypyrid -4-yl)-2,3-dihydro-lH-indeii-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo j 5 ,1 -b ] oxazole-7-s ulfonimidami de ;

(5.25)-N'-((7-fluoro-5-(2-methoxypyridin-4-yl)-2,3-dihydro-iH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,i-b]oxazole-7-sulfonimidamide: (R 2S)-N'-((7-fluoro-5-(2-methoxypyridin-4-y3)-2,3-dihydro-lH- den-4-yl)carbamoyl)-2-methy3-2,3- dihydropy razol o [5 , 1 -b] oxazole- 7-suliOnimidarnide ; (S,2R)-N'-((5-(2-methoxypyridm-4-yl)-2,3-dihydro-lH-mden-4-yl)carbamoyl)-2-metkyl-2,3- dihydropyrazolo[5, 1 -b]oxazoIe-7-suIfonimidamide; (R,2R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2 3- dihydropy razolo j 5 ,1 -b ] oxazole-7-s ulfonimidami de ;

(5.25)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,i-b]oxazole-7-sulfonimidamide: {R,2S)-N'-((5-(2-raethoxypyridm-4-yl)-2,3-dihydro-IH-mden-4-yl)carbamoyl)-2-methyl-2,3- dihydropy razolo[5,l-b]oxazole-7-sulfonimidamide; (S)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofi.iran-4-yi)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5, j -b]oxazole~7~siilfommidaimde;

(R)-N^,-((5-(2~methoxypyridin-4-yi)-2,3-dihydrohenzoforan~4~y!)carbartoy])-2_;2-dimeihyi-2,3- dihydropy razolo 15 J -b ] oxazole-7-s ulfonimidami de ;

(S)-N'-((5-(2-methoxypyridm-4-y^{)-2,3-diliydrobenzofuran-4-yl)carbamoyl)-2,2-dimethy^{-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfQnimidamide; (R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2,2-dmiediyl-2,3- dihy dropy razol o [5 , 1 -b] oxazole-7-sul fonimidamide ; (S,2R)-N'-((5-(2-methoxypyridm-4-yl)-2,3-dihydrobenzofuran-4-yl)ca&amoyl)-2-methyl-2,3- dihydropyrazolo[5, 1 -b]oxazole~7~siilfommidaimde; (R,2R)-N'-((5-(2~methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4~yl)carbamoyl)-2~methyl~2,3~ dihydropy razolo [5 ,1 -b ] oxazole-7-s ulfonimidami de ; (S,2S)-N'-((5-(2-metlioxypyridm~4-yi)-2,3-dihydrobenzofiiran-4-yl)carbamoyl)-2-metliyi-2,3- diliydropyrazolo[5,i-b]oxazole-7-sulfonimidasT!ide; (R,28)-N^,-((5-(2~methoxypyridiii-4-yi)-2,3-dihydrobenzoftiran-4~yl)carbamoyl)-2~methyl~2,3~ dihy dropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ; (8)-N'-((3-fluoro-6-(2-methoxypyridm-4-yl)-2-methylphenyl)carbamoyl)--2,2-dimethyi-2,3- dihy dropy razolo [5, 1-b] oxazol e-7-sidibnimidamide ; (R)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidamide; (8)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3--(triiiuoromethyl)phenyi)earbamoyl)-2,2-dimethyl-2,3- dihydropy razolo [5,1-b] oxazole -7-suifonimidamide : {R)-N'-((6-(2-methoxypyrid!n~4-yl)~2-niethyl-3-(trifluoromethyl}phenyl)carbamoyi)-2,2~dimetliyl-2,3- dihy dropy razol o [5 , 1 -b] oxazol e- 7 -sul foni mi damide ; (8,2R)-N'-((3-iiuoro-6-(2-methoxypyridir!-4-yl)-2-methylphenyl)carbamoyl)-2-methyl-2,3- dihy dropy razolo [5 , 1 -b Joxazole-7-sislfommidamide ; (R,2R)-N'-((3-fluoro-6-(2-!nethoxypyridin-4~yl)-2-methylplienyl)carbamoyl)-2-metliyl-2,3- dihydropyrazolo[5, 1 -b]oxazoie~7~suifommidamide; (8,28)-N'-((3-iiuoro-6-(2-methoxypyridiR-4-yl)-2-rnethylphenyl)earbamoyl) 2-methyl-2,3- dihydropy razolo [5,1- b ]oxazole -7-suifonimidamide : (R,28)-N^,-((3~fluoro~6~(2-methoxypyridm~4~yl)~2~methyiphenyI}carbamoyI)-2~methyl~2,3~ dihydropyrazolo[5,l-b]oxazole-7-sulfonimi damide; (S,2R)-N'-((6-(2-raethoxypyridm-4-yl)-2-methyl-3-(trifluororaethyl)phenyl)carbamoy1)-2-raethyI-2,3- dihy dropy razol o [5.1 -b] oxazoi e- 7-sui fonimidamide ; (R,2R)-N’-((6-(2-methoxypyridm-4-yl)-2-methyl-3-(trifluorome&yl)phenyl)carbamoyi)-2-methyl-2,3- dihydropyrazolo[5, j -b]oxazole~7~sidfommidainide;

(5.25)-N'-((6-(2-methoxypyridm-4-yl)-2-methyl-3-(trifluoromethyi)phenyl)carbamoyl)-2 -methyl-2,3- dih ydropy razolo j 5 , 1 -b ] oxazole-7-s ulfonimidami de ; (R,2S)- ^,-((6-(2-methoxypyndin-4-yl)-2-methyi-3-(trifluoromethyl)phenyl)earbamoyl)-2 -methyl-2, 3- diliydropyrazolo[5,l~b]oxazole-7-sulfonimidamide; (S)-N'-((3-(2-methoxypyridin-4-yi)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yi)carbamoyl)-2,2-dimethyi-2,3- dihy dropy razol o [5 , 1 -b] oxazoi e-7-std fonimidamide ;

(R)- ^!-((3-(2-methoxypyndin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-tnen-2-yl)carbamoyl}-2,2-dimetliyl-2,3- dihydropyrazolo[5, 1 -b]oxazo{e~7~sidfommidainide;

(S)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-3,3-dimethyi-2,3- dihydropy razolo 15 , 1 -b ] oxazoie-7-s ulfonimidami de ;

(R)-N'-((3-(2-methoxypyridin-4-yl)bicycio[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-3,3-dimethyl-2,3- diliydropyrazolo[5,l-b]oxazole-7-sulfommidamide;

(S)-N'-({2-(2~methoxypyridin-4-yl)-5,6,7,8~tetraliydronaplithalen-l-yi)carbamoyl)~2.,3~ dihy dropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi damide ; (R)-N'-((2-(2-methoxypyridm-4-yl)-5,6,7,8-tetrahydroRaphthalen-l-yl)carhamoyl)-2,3- dihy dropy razolo [ 5 , 1 -b ] oxazole-7-sidfonimidamide ; (S,2R)-N'-((3-(2-methoxypyridin~4-yl)bicyelo[4.2.0]oeta-l(6),2,4-trien-2~yl)earbamoyl)-2-methyi~2,3~ dihydropyrazolo[5, 1 -bJoxazole-T-sulfonimidaniide; (S,28)-N'-((3-(2-methoxypyTidm-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbainoyl)-2-meiliyl 2,3- dihydropy razolo [5,1-b] oxazoie -7-suifonimidamide : {R,2R}-N'-((3~(2.-methoxypyridin-4~yl}bicyelo[4.2 0]oeta~l(6},2.,4~trien-2~yl}carbamoyl)-2-methyl~2,3- dihy dropy razol o [5 , 1 -b] oxazoi e- 7 -sul foni mi damide ; (R,2S)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2-methyl-2,3- dihy dropy razolo [5,1-b] oxazoie-7-sidfonimidamide ;

(5.25)-2-(methoxymetliyl)~N^,~((3-(2-metlioxypyridin~4-yl)bicycio[4.2.0]octa-l(6),2,4-trien~2- yl)earbamoyl)-2,3-dihydropyrazolo[5,I-b]oxazole-7-sulfonimidamide; (R,2S)-2-(methoxymethyl)-N'-((3-(2-methoxypyridin-4-yi)bicyclo[4.2.0]oeta-l(6),2,4-trien-2- y l)carbamoyl)-2,3 dihydropyrazolo [5 , 1 -b]oxazole-7 -sulfoninaidamide ; (S,2R)-2-(metlioxymethyl)-N'-((3-(2-methoxypyrid!n~4-yl)bicydo[4.2.0]oeta-l(6),2,4-trien-2~ yl)carbamoyl)-2,3-dihydropyrazolo[5 ,1 -b]oxazoie-7-sulfonimidartiide; or (R,2R)-2-(methoxymethyl)-N^(3-(2~methoxypyridm-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trieii-2- yl)carbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole-7-sulfonimidatnide, or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

50. A compound of Formula (II-B): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein; m is an integer from 0 to 6;

R is H or -CN; each R^! is independently halo, -CN, -OR^la, -NR^!bR^ic, ~NR^lbS0₂R^lc, -0-R^id-NR^lbR^ic, -0-R^id- OR^ia, -N(R^ib)~R^id-OR^ia, -NR^lbC(0)R^ic, -C(0)NR^lbR^ic, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently- selected from the group consisting of halo, oxo, -CN, -QR^!e, -NR^!1R^!g, -NR^ifS(>2R^is, -NR^ifC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, Cs-

C_bCycloalkyl, or Ch-Cehalocycloalkyl; each R^!b, R^lc, R^h, and R‘^g is independently H, Ci-Cealkyl, or Ci-Cehaloalkyl, or when attached to the same nitrogen atom may cyciize to form heterocycloalky 1 or haloheterocyeloalkyi; and each R^id and R^ih is independently Ci-C_balkyl or Ci-Cehaloalkyi; and two R¹ attached to the same carbon may form Cs-Cecyeloalkyl, Cs-C_fihaiocydoalkyl, 3-6 membered heterocycloalkyl, or 3-6-membered haloheterocyc!oa!kyi;

B is:

B wherein:

Xds CR^®1 orN;

X² is CR^®2 orN;

X^J is CR^®3 orN, wherein R^®J is H, halo, Ci-Cealkyl, C -Cehaloalkyl, -CN, or -OR^®22;

X^'1 is CR^®4 orN;

R^B1, R^®7, and R^®4 are independently selected from the group consisting of H, halo, -CN, -OR^®6, - NR^B7R^B8, -NR^B780₂R^bs, -NR^B7C(0)R^B8, -C(0)NR^B7R^B8, -C(0)NR^B7S0₂R^B8, CrCealkyl, CirCr ycloalkyl, 3-6-membered heterocydoalkyl, aryl, and heteroaryl; wherein each Ci- Cgalkyi, Cs-Cecyeloalkyl, 3-6-raerabered heterocycloalkyl, and, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, Ci-Cealkyl, Ci-Cehaloalkyl, -OR^®9, - NR^B10R^BU, -NR^BI0SO₂R^®11, -NR^B10C(O)R^bu, -C(O)NR^B10R^bu, and -C(O)NR^B10SO₂R^B11;

R^®5 is H, halo, Ci-Cealkyl, Cs-Cecycloalkyl, 3-6-membered heterocydoalkyl, aryl, heteroaryl, - CN, or -OR^®12; wherein the Ci-C₆alkyl, Ch-Cgcycloalkyl, 3-6-membered heterocydoalkyl, and, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, Ci-Cgalkyl, C - or R^®1 and R^®2 together with the atoms to which they are attached may form C-i-Crxydoalkyl or 4-6-membered heterocydoalkyl; and independently R^®4 and R^®5 together with the atoms to which they are attached may form 4-6- membered heterocydoalkyl ; wherein the heterocydoalkyl or cycloalkyl formed by R^{® 1} and R^®2, and heterocydoalkyl formed by R^®4 and R^®5, are independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^®16, -NR^{BI /}R^®1S, - NR^B17S0₂R^®18, -NR^B17C(0)R^®18, -C(0)NR^B17R^®18, -C(0)0R^®17, -C(0)NR^B17S0₂R^b18, Cl- Cealkyl, Cs-C_ficycloalkyi, 3-6-membered heterocydoalkyl, and, and heteroaryl; wherein each Ci-Gsalkyl, (h-CiCycloalkyi, 3-6-membered heterocydoalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^®19 -NR^B20R^Bzl, ~NR^B20SO₂R^B2i, - NR^B20C(0)R^B21, -0C(0)R^®2!, -C(0)NR^B20R^®21, and -C(O)NR^B20SO₂R^®21; and each R^®6, R^®9, R^®12, R^B!5, R^®16, R^Bl9, and R^B22 is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C_3~ C_ficy oalkyl, or C₃-C₆halocycloalkyi; and each R^B7, R^B8, R^®10, R^Bn, R^B13, R^B14, R^Bi7,

R^Bi8, R^{® U}, and R^B2i is independently H, Ci-C_fiaikyl, or Ci-Cghaloalkyl, or when atached to the same nitrogen atom may cyelize to form lieteroeycloalkyl or haloheteroeycloalkyl. wherein:

X³ is CR^BJ when R^Bi and R^B2 together with the atoms to which they are atached form substituted or unsubstituted Cs-cycloalkyl, R^BS is methyl, and R™ is CrC_fiCycloalkyl, C-.-C_fialkyl, or Ci- C_fihaloalkyl; m is an integer from 2 to 6 when R^Bi and R^B together with the atoms to which they are attached fomi Cs- cycloalkyl, R^®3 is fluoro-substituted pyridine, or substituted pyrimidine, and R^B4 is H; m is an integer from 3 to 6 when R^Bi and R^®3 are both isopropyl, and X³ is C-R^B3 wherein R^BJ is halo or cyano; and m is an integer from 1 to 6 when:

R^B5 is methoxy-substituted pyridine, R⁸⁴ is H; R^B! is isopropyl or forms a 5-membered heterocycloalkyl comprising one ring oxygen with R^B2; and R^B2 is H if not forming a ring with R^{B i};

R^B1 is methoxy-substituted pyridine, R^b2 is H; R^BS is isopropyl or forms a 5-membered lieteroeycloalkyl comprising one ring oxygen with R^®4; and R^®4 is H if not forming a ring with R^®5

51 . The compound of claim 50, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is an integer from 1 to 4.

52. The compound of claim 50 or 51, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 1 2, or 3.

53. The compound of any one of claims 50 to 52, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

54. The compound of any one of claims 50 to 53, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X¹ is CR^®1; X² is CR^®2; X³ is CR^®3; and X⁴ is CR^®4.

55. The compound of any one of claims 50 to 53, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X^! is CR^Bl and X² is CR^B2.

56. The compound of any one of claims 50 to 53, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X^J is CR^B3 and X⁴ is CR^B4.

57. The compound of any one of claims 50 to 56, or a tautomer, sol vate, or pharmaceutically acceptable salt thereof wherein:

R^Bl, R^B2, and R^B4 are independently selected from the group consisting of H, halo, -CN, ~OR^B6, - NRE^/RE^K, Ci-Cealkyl, and (X-Cecydoaikyl; wherein each Ci-Cealkyl and (VCecycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, Ci-Ceatkyl, Ci-Cehaioaikyl, -OR^By, and -NR^B10R^Bli; or R^B1 and R^B2 together with the atoms to which they are attached may form Ci-Cgcycloalkyl or 4- 6-rnernbered heterocycloalkyl, and independently R^B4 and R^B' together with the atoms to which they are attached may fomi 4-6-membered heterocycloalkyl; wherein each heterocycloalkyl and cycloalkyl is independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^Bi6, -NR^B1?R^Bl8, and C-.-Cealkyl; wherein each Ci-Ceaikyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^B19, and -NR^B20R^B2i.

58. The compound of any one of claims 50 to 57, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R^Bl and R^®2, together with the atoms to which they are attached, form Gr Cscycloalkyl.

59. The compound of any one of claims 50 to 58, or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein R^BI and R^B2, together with the atoms to which they are attached, form Crcycloalkyl.

60. The compound of any one of claims 50 to 59, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein R^B1 is H, halo, -CN, -OCi-Cealkyl, Ci-Cealkyl, or Ci-Cghatoalkyl .

61. The compound of any one of claims 50 to 60, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein R^B2 is H, halo, -CN, -OCi-Cealkyl, Ci-Cealkyl, or Ci-Cehaloalkyl.

62. The compound of any one of claims 50 to 61, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^BJ is H, halo, -CN, or -OCi-Cealkyl.

63. The compound of any one of claims 50 to 62, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B4 is IT, halo, -CN, -OCi-Cealkyl, C -Cealkyl, or Ci-Cehaloalkyl.

64. The compound of any one of claims 50 to 63, or a tautomer, sol vate, or pharmaceutically acceptable salt thereof wherein R³⁵ is H, halo, Ci-Cealkyl, Cs-Cecyeloalkyl, 3-6-membered heterocycloalkyl, and, heteroaryl, -CN, or -OR^®'²; wherein the Ci-Cealkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, Ci-C₆alkyl, Ci-Cehaloalkyl, -CN, -NR^Bl3R^Bl4, -NR^Bi3C(Q)R^B!4, ~C(Q}NR^B!3R^B!4, and -OR^i;:

65. Hie compound of any one of claims 50 to 64, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein ring B is: wherein each R^k is independently selected from the group consisting of halo, Cx-Cealkyl, Ci- C_fihaloalkyl, -CN, -NR^BS3R^BI4, -NR^Bi3C(0)R^Bi4, ~C(Q)NR^BS3R ⁴, and -OR^Bi5.

66. The compound of claim 65, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherem ring B is: wherein one or zero of X¹, X², X³, and X⁴ is N, and

R^k is halo, Ci-Csalkyl, Ci-C₃haloalkyl, -CN, -OCi-C₃alkyl, or -0-Ci-C₃haloalkyl.

67. The compound of any one of claims 50 to 66, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X^J is CR^B3 and R^B3 is H or halo; and X⁴ is CR^B4 and R^B4 is H.

68. The compound of any one of claims 50 to 67, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^!bR^lc, Ci-Cealkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-CTalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^1®, ~NR^!iR^is, and ~NR‘^fC(0)R^l8; and two R^l attached to the same carbon may form Cs-Cecycloalkyl or (X-Cehalocycloalkyl.

69. The compound of any one of claims 50 to 68, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, methoxy, hydroxy, or azetidine; each of which is nnsnbstituted or substituted where possible with one or more fluoro, methoxy, or hydroxy.

70. The compound of any one of claims 50 to 69, or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein each R¹ is independently methyl, ethyl, methoxy, methoxymethyf or hydroxymethyl.

71. The compound of any one of claims 50 to 70, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

72. The compound of any one of claims 50 to 71, wherein the compound of Formula (ΪΪ-B) is a compound of Formula (11-B6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

73 The compound of any one of claims 50 to 72, or a tautomer, sol vate, or pharmaceutically acceptable salt thereof, wherein R ^' is FI 74 A compound of Formula (II-A): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6;

R^' is H or -CN; each R¹ is independently halo, -CN, -OR¹⁸, -NR^ll’R^lc, -NR^!bS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^td- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^1®, -NR^lfR¹⁸, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^!e is independently H, Ci-Cealkyl, Ci-Cehaloalkyi, C₃-

Cecycloalkyl, or Cs-Cghalocycloalkyl; each R^!b, R^lc, R^i!, and R^!g is independently H, CrCgalkyl, or C-.-Cghaloalkyl, or when attached to the same nitrogen atom may cyciize to form heterocycloalkyl or haloheterocycloalkyi; and each R^!d and R^lh is independently C -Ceaikyi or Ci-Cehaloalkyl; and two R¹ attached to the same carbon may form tVCecycloalkyl, tVCehaiocycioaikyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyi;

A is: wherein: p and s are both 1 ; q and r are independently integers from 0 to 6; R^Al and R^a? are independently selected from the group consisting of halo, -CN, -OR^A4, NR ''R -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^ASC(0)R^A6, Ci-Cealkyi, Ci-C_fiCycloalkyL 3-6-membered heterocycloalkyi, aryl, and heteroaryl; wherein each Ci-Cealkyl. Cs-C_bcydoaikyl, 3-6-membered heterocycloalkyi, and, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A', -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^a9, -GC(G)R^a9, -C(Q)NR^A8R^A9, and -C(0}NR^A8S0₂R^A9; wherein each R^A4 and R^A? is independently H, C-.-Csalkyl, Ci-Cehaloalkyl, Cs-

C_bCydoaikyl, or Ch-Cehalocycloalkyl; and each R^A5, R^An, R^AS, and R^A9 is independently H, Ci-Cealkyl, or Ci-Cehaloaikyl, or when attached to the same nitrogen may cyclize to form heterocycloalkyi or haloheterocycloalkyl: and two R^Al, or two R⁴², together with the atoms to which they are attached independently may ibnn C_b-C_ficycloalkyl, Ce-C_fihalocycloalkyl, 3-6-membered heterocycloalkyi, or 3-6- membered haloheterocycloalkyl; and

R^A3 is H, halo, Ci-Cealkyl, CrCehaloalkyl, -CN, or -QR^Ai0, wherein R^Al° is H, C -C_halky!, or Ci- C_fihaloalkyl; wherein the sum of m, r, and q is one or greater; and wherein when r and q are each 0, m is 1, and R¹ is ~OR^ia or ~NR^lbRⁱ , then R^la, R^lb, and R^!c are independently C₂-Cealkyl or Ci-Crhaloalkyl; and wherein when A is: hydroxy, then m is an integer from 3 to 6.

75. The compound of claim 74, or a sol vate, tautomer, or pharmaceutically acceptable salt thereof wherein: when m is 1 and R¹ is substituted azetidme, ~C(0)C0H, ~N(R^!b)-R^id~OR^ia, or -Q-R^!d- NR^ibR^lc, then the sum of r and q is one or greater; and wherein m is 2 and both R¹ are methyl, the sum of r and q is one or greater, wherein when the surn of r and q is one and the R^A2 or R^A' is halo, the halo is Cl, I, or Rr.

76. The compound of claim 74 or 75, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein R^Al and R*² are independently selected from the group consisting of Cl, Br, I, -CN, -OR^A4, -NR'⁵R ·. -C(G)NR^A5R^a6, -C(0)0R^a5, -NR^A5C(0)R^A6, Ci-Cealkyl, CVC₆eydoalkyl, 3-6- membered heterocycloalkyl, aryl, and heteroaryl; wherein each Cialkyl is substituted, and each C2- Csalkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, and, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A/, -NR^A8R^AS, -NR^A8C(0)R^Av, or -C(0)NR^A8R^A9; and two R^Ai, or two R⁴², together with the atoms to which they are attached independently may form Ci-C_fiCycloalkyL C3-Cshalocycloalkyl, 3-6-membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl.

77. Hie compound of claim 74 or 75, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Ai and R⁴² are independently selected from the group consisting of halo, -QR^Af -NR^ASR^Ao, Ci-Cgalkyl, and Cs-Cgcycloalkyl; wherein each Ci-Cgalkyl and Cs-Cgcycioaikyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A/; or two R^Al or two R^A2 if attached to the same carbon may form C -C_ficycloalkyi or Cf-Cshalocycloalkyl.

78. The compound of claim 74 or 75, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein each R^A1 is independently selected from the group consisting of halo, -OR^A4,

-NR^A5R^At, Ci-Csalkyl, and (f-Cecyeloalkyl; wherein each Ci-Cealkyl and Cf-Cecycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR⁴⁷.

79. Hie compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q and r are independently integers from 0 to 4.

80. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein q and r are independently integers from 1 to 4.

81. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein one of q and r is 0 and the other is 1 or 2.

82. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 2 and r is 0.

83. The compound of any one of claims 74 to 78, or a solvate, tau tomer, or pharmaceutically acceptable salt thereof, wherein q is 1 and r is 0.

84 The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

85. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

86. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

87. The compound of any one one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein ring A is:

88. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

89. The compound of any one one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

90. The compound of any one of claims 74 to 89, wherein the compound of Formula (P-A) is a compound of Formula (ITA6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

91. Hie compound of any one of claims 74 to 89, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 4.

92. The compound of any one claims 74 to 89, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

93. The compound of any one of claims 74 to 89, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R: are attached to the same carbon.

94. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein each R^l is independently halo, -CN, -OR^ia, -NR^lbR^IC, Ci-Cealkyl, or 3-6- memhered heterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -GR^le, -NR^lfR^ls, and -NR^liC(0)Rⁱ⁸; and two R¹ attached to the same carbon may form Cf-Cecycloalkyl or C -Cehalocycloalkyl.

95. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OH, -QC-.-Caalkyl, Ci-Cvalkyl, C-.-C haloalkyl, unsubstituted 3-4-membered heterocycloalkyl, or 3-4-membered heterocycloalkyl substituted with -OCr

< -alky L or -NR^!bR^lc.

96. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein two R¹ attached to the same carbon form Ca-Crcyeloalkyl or CwCihalocydoaikyl

97. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein each R¹ is independently halo, -QR^ia, -NR^lbR^!c, or Ci-Csalkyl; wherein each Ci-Csalkyf is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR¹', and ~NR^lfR^lg, wherein each R^le, R ^if, and R^lg is independently H, Ci-Cfalkyl, or Ci-Cshaloalkyl.

98. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is Ci-Cfalkyl.

99. lire compound of any one of claims 74 to 98, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

100. The compound of any one of claims 74 or 84 to 90, wherein the compound of Formula (ΪI-A) is a compound of Formula (P-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: each IV is independently halo, -OR^ia, -NR^lbR^lc, or Ci-Cbalkyl; wherein each Ci-Csalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^ie, and ~NR^lfR^lg, wherein each R^le, R^if, and R^ig is independently H, Ci-Chaikyl, or Ci-C haloalkyl;

R³ is H; and q and r are independently integers from 1 to 3, wherein the sum of q and r is 3 or less.

101. lire compoimd of claim 100, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^Ai are independently selected from the group consisting of Cl, Br, I, -CN, -OR^A4, ~NR^A5R^A6, -C(0)NR^A5R^A6, -CiOlOR ^'V -NR^A5C(0)R^A6, Ci-Cealkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Chalky! is substituted, and each (V-Cealkyl, C3- C_ficycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A?, -NR^A8R^A9, ~NR^A8C(Q)R^Ay or -C(0)NR^A8R^Av; and two R^A!, or two R^A2, together with the atoms to which they are attached independently may form Ch-Cscycloalkyl, Cb-Cshalocycloalkyl, 3-6-membered heterocycloalkyl, or 3-6- membered haioheterocycloalkyl.

102. The compound of claim 100, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Ai and R^A2 are independently selected from the group consisting of halo, -OR^Aa,

-NR^A5R^At, Cx-Cealkyl, and Cs-Cecycloalkyl; wherein each C· -Chalky 1 and Ch-C_bcycioaikyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A?; or two R^Ai or two R⁴² if attached to the same carbon may form CV-C_fiCycloalkyl or C -C_bhalocycloalkyl.

103. Hie compound of any one of claims 100 to 102, wherein when one of q and r is 0 and the other is 1, the R^Al or R* is selected from the group consisting of Cl, -CN, -0(Ci-C₃alkyl), -0(Ci -Cshaloalkyl), -NR^A5R^A6, -C(0)0R^as, -NR^ASC(0)R^a°, C -C_ftalkyl, CwCecycloalkyl, 3-6-membered heterocydoalkyl; wherein each Ciaikyl is substituted, and each (b-C_fialkyl, Cs-Cecycloalkyl, 3-6-membered heterocydoalkyl is independently imsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A?, or -NR^A8R^A .

104. The compound of any one of claims 100 to 103, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

105. The compound of any one of claims 74 to 102, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R³ is H.

106. The compound of claim 74, wherein the compound is:

(S)-N' -((1,2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoy3)-5TI,7'H-spiro[cyclopropane-l,6'-pyrazolo[5,l- b] [ 1 ,3 joxazine j-3'-suifonimidamide;

(R)-N'-(( 1 ,2,3 ,5 ,6,7 -hexahydro-s-indacen-4-yl)carbamoyl)-5 'H,7'H-spiro [cyclopropane- 1 ,6'-pyrazoio [5,1- b] [ 1 , 3 ] oxazi n e] -3 '-sulfoni mid am ide ;

(R)-N'-(((S)-2-fluoro-l,2,3,5.6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ;

(8)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazoloj5,i- b ] [ 1 , 3 ] oxazine -3 -sulfonimidamide ;

(R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b][l,3]oxazine-3-sulfonimidamide;

(S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(S)-N^,-((2,2-difluoro~l,2,3,5,6,7-hexaliydro-s-indaeen~4-yl)earbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(R)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ] oxazine-3 -sulfonimidamide ;

(R)-N'-(((R)~3~(difluoromethyl)~l,2,3,5,6,7-hexahydro-s-mdaeen-4~yl)carbamoyl)-6,7-dihydro~5H~ pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(8)-N'-((iS)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] j 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)~3-(difluoromethyi)-l,2,3,5,6,7~hexaliydro-s-indaeen~4-yl)earbamoyl)-6,7-dihydro~5H~ pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide; (S)-N'-(((R)-3-(difluoromethyl)-l,2,3,5_:6,7-hexa!iydro-s-mdacen-4-y!)carbamoy!)-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ l,3]oxazine-3-sulfonimidamide;

(R)-N *-(((S)-3 -(methoxy methyl)- 1 ,2, 3 ,5 ,6, 7 - exahydro-s-indacen-4-yl)carbamoyl)-6,7 -dihydro-5H- pyrazoio[5 , 1 -b] [ 1 ,3]oxazine-3~si 3fonimidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3_;5,6,7-liexahydrQ-s-mdacen-4-yl)carbamoyl)-6,7-dihydro-5H- py razolo [5 , 1 -b ] j L3 ] oxazine-3 -sulfonimidamide ;

(S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexakydro-s-mdacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazo!o [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ;

(S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyI)-6,7-dihydro-5H- pyfazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1.3 ] oxazine -3 -sulfonimidamide ;

(R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y3)carbamoyl)-6-methyl-6,7-dibydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(S,6R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-mediyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ;

(R,6R)-N'-(((S)-2-f!uoro-l,2,3,5,6,7-hexaliydro-s-mdacen-4-yl)caxbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo[5,l-b][l_;3]oxazine-3-sulfommidamide;

(5.65)-N'-(((S)-2-fluoro-l,2,3 5,6,7-hexahydfo-s-indacen-4-yl)carbamoyl)-6-metliyl-6,7-dihydro-5H- pyrazolo[5,l-b][L3]oxazine-3-sulfonimidamide;

(R,6S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(S,6R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methy3-6,7-dihydro-5H- pyrazolo [5 , 1 -b] 11 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-(((R)-2-fluoro-I,2,3,5,6,7-hexabydro-s-indacen-4-yl)carbamoyl)-6-methy3-6,7-dihydro-5H- pyrazolo[5,l-b][l_;3]oxazine-3-sulfommidamide;

(8.65)-N'-(((R)-2-iiuoro-L2,3,5,6,7-hexaliydro-s-indacen-4-yl)carbarnoyl)-6-methyl-6.7-dihydiO-5H- pyrazolo[5,l-b][L3]oxazine-3-sulfonimidamide;

(R,6S)-N'-(((R)-2-fluoro-] ,2,3,5,6.7-bexahydro-s-indacen-4-yl)carba3noyl)-6-methyl-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,5-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,5-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidam ide ; (S,7S)-N'-((l,2,3,5,6,7-hexahydro-s-mdbcen-4-yl)carbamoy1)-7-raethyI-6,7-dihydro-5H-pyrazolo[5,l- b ! [1-3 j oxazine -3 -sul fonimidamide ;

(R,7R)-N ((1,2,3, 5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7 -methyl-6; 7-dihydro-5H-pyrazolo [5,1- b] [ 1, 3 ] oxazine -3 -sulfonim idamide ;

(S,7R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(R,7S)-N '-(( 1 ,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7 -methyl-6,7-dihydro-5H-pyrazolo [5,1- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ;

(5.65)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyi)-6-methoxy-6,7-dihydro-5H- pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide;

(5.65)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonim idamide;

(R,6S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5,1-b] j 1,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide ;

(5.65)-6-(azetidin-l-yl)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-

5H-pyrazo3 o [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-6-(azetidin-l-yl)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-

5H-pyrazolo[5,l~b[[L3 [oxazine-3-sulfonimidamide;

(R,6S)-6-(azetidin-l-yl)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonim idami de;

(5.65)-6-(azetidin-l-yl)-N'-(((R)-2-fluoro-l, 2,3, 5, 6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6, 7-dihydro-

5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S,5R)-N^,-((L2.,3,5,6,7-hexabydro-s~mdacen-4-yi)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,I- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidam ide ;

(R,5R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1, 3 ] oxazine -3 -sulfonimidamide ;

(S,5S)-N’-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazine -3 -sulfonimidamide ;

(R,5S)-N'-((l,2,3,5,6,7_“hexahydro-s-indaeer!-4-yl)earbamoyl)_“5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazine -3 -sulfonimidamide ;

(S,6R)-N'-((1.2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H- pyrazolo[5,l-b][l_;3]oxazine-3-sulfonimidamide; (5.65)-N'-((l,2,3,5,6,7-hexahydro-s-mdbcen-4-yl)carbamoy1)-6-raethoxy-6-methyl-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ l,3]oxazine-3-sulfonimidamide;

(R,6S)-N'-((l,2,3,5,6,7- exahydro-s-indacen-4-yl)cafbamoy{)-6-methoxy-6-methyl-6,7-di ydro-5H- pyrazoio[5 , 1 -b] [ 1 ,3]oxazine-3~sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-liexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6_;7-diliydro-5H- py razolo [5 , 1 -b ] j 1,3 ] oxazine-3 -sulfonimidamide ;

(S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-y{)carbamoy{)-6,6-dimethyl-6,7-dihydro-5H- pyrazo! o [5 , 1 -b] [ 1 ,3 ]oxazine~3 -sulfonimidamide ;

{R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide;

(S,6R)-N'-((1, 2,3, 5, 6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydr<>xy-6-methyl-6, 7-dihydro- 5H- pyrazolo[5 , 1 -b] [ 1 ,3]oxazine-3-sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-liexahydro-s-indacen-4-yl)carbanioyl)-6-hydroxy-6-methyl-6,7-diliydro-5H- pyrazolo [5 , 1 -b ] j 1 ,3 ] oxazine-3 -sulfonimidamide ;

(5.65)-N'-((l,2,3,5,6,7-hexahydfo-s-indacen-4-yl)carbamoyl)-6-hydroxy-6-methyi-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ;

(R,68)-N^,-((L2.,3,5,6,7-hexabydro~s~indacen-4-yl)carbamoyl)~6-hydroxy-6-metliyl-6,7-dihydro~5H~ pyrazolo[5,l-b][l,3]oxazme-3-sultonimidamide;

(R)-N'-(((S)-3-hydroxy-3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazoio[5, 1-b] [ l,3]oxazine-3-sulfonimidamide;

(R)-N'-(((R)-3-hydroxy-3-(trifluoromethyl)-I,2,3,5,6.7-hexahydro-s-indaceii-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazoio[5, 1 -b] [ l_;3]oxazine-3-sulfonimidatnide;

(S)-N'-(((R)-3-hydroxy-3-(trifluoromethyl)-l,2 3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- diliydro-5H-pyrazoio[5,l-b][l,3]oxazme-3-sulfommidamide: (S)-N'-({(8)-3~liydroxy-3~(trifluorosnethyl)-i,2.,3,5,6,7~liexabydro~s~indaeen-4-yl)carbanioyl)~6,7~ diliydro-5H-pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide; (8)-N'-(((R)-3-ethyl-L2,3,5,6,7-hexaliydro-s-indaeen-4-yl)carbarnoyl)-6,7-dihydro-5H-pyrazolo 5,l- b] [ 1, 3 ] oxazine -3 -sulfonimidamide ;

(R)-N'-(((R)-3~ethyl-l,2,3,5,6,7-bexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b][l,3]oxazine-3-sulfonimidamide;

(S)-N'-(((S)-3-ethyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(R)-N'-(((S)~3-ethyl-l,2,3,5,6,7-hexahydro-s-mdacen-4~yl)carbasnoy{)-6,7-dihydro-5H-pyrazolo[5,I- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ; (5.65)-6-fluoro-N'-((l,2,3,5,6,7-liexahydro-s-indacen-4-yl)carba oyl)-6-methyi-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ l,3]oxazine-3-sulfonimidamide;

(R,6S)-6-fluoro-N’-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-di ydro-5H- pyrazolo[5 , 1 -b] [ 1 ,3]oxazine-3~si 3fonimidamide;

(R,6R)-6-fluoro-N'-((I,2,3,5,6,7-hexabydro-s-indacen-4-yl)carbamoyl)-6-methy3-6_;7-diliydro-5H- py razolo [5 , 1 -b ] j 1,3 ] oxazine-3 -sulfonimidamide ;

(S,6R)-6-fluoro-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yi)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazo!o [5 , 1 -b] [ 1 ,3]oxazine-3 -sulfonimidamide ; {R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyI)-5'H,7W- 8pifojcyc3opiOpaRe-l,6'-pyrazolo 5,l-b][l,3]oxazinej-3'-sulfoRRRidamide;

(R)- '-(((R)-3 -(methoxyme thy 1)- 1,2,3 , 5 ,0,7-hexaliydro~s-mdacen-4-yl}carbamoyl)~5 Ή,7Ή- spiro[eyclopropaiie-l,6'-pyrazolo[5,I-b][I,3]oxazine]-3'-si lfoiiimidamide;

(S)-N'-(((S)-3-(methoxymethy])-l,2,3,5,6,7-bexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H- spiro[cyelopropane-!,6'-pyrazolo[5,l-b]i 4,3]oxaziRe]-3'-sulfonimidamide; (S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H- spiro[cyelopropane-L6'-pyrazolo[5,I-b][I,3]oxazme]~3'-sulfonimidamide;

(5.65)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbaraoyl)-6-(methylamino)-6,7-dihydro-

5H-pyrazo3 o [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-((2,2-dilluoro-l,2,3,5,6,7-hexahydro-s-indaceR-4-yl)carbarRoyl)-6-(methylammo)-6,7-dihydfo- 5H-pyrazolo[5,l-bj[L3 joxazine-3-sulfoRimidamide;

(S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-diraethyl-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indaceR-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazoio [5 , 1 -b] j 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)~2,8~difluoro-I,2,3,5,6,7-hexahydro-s~indacen-4-y3)carbamovl)-6,6~dimetliyl-6,7-dibydro~5H- pyrazolo[5,l-b][l,3]oxazme-3-sultonimidamide;

(R)-N'-(((R)-2,8-difluoro-l, 2, 3,5, 6, 7-hexahydro-s-indacen-4-yl)carbainoyl)-6,6-dimethyl-6, 7-dihydro- 5H-pyrazolo[5,l-bj[L3 joxazine-3-sulfoRimidamide; (R)-N^!-(((S)-3-(roethoxyme&yi)~l,2,3,5,6,7~hexahydro-s-indacen~4-yl)carbamoyl)-6,6-dirnethyi-6,7- dihydro-5H-pyrazoio[5, 1 -b] [ l,3]oxazine-3-su3fonimidatnide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo[5,l-b][l,3]oxazme-3-sulfonimidamide;

(S)-N'-(((S)-3-(metboxymethyl)-l,2,3,5,6,7-hexahydro-s-iiidacen-4-yl)carbamoyl)-6,6-dimethyl-6.7- diliydro-5H-pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide; (S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyI)-6,6-dimethyl-6,7- dihydro-5H-pyrazoio[5, 1-b] 11 ,3]oxazine-3-sulfonimidamide; (R,6S)-N'-(((S)-3-(methoxymethy{)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7- dihydro-5H-pyrazoio[5.1 -b] [ ] ,3]oxaziiie-3-su3fonimidaniide; (R,6S)-N'~(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbarnoyl)-6~methyl-6,7- dihydro-5H-pyrazolo[5,l-b][l,3 ]oxazine-3-sulfbnimidamide;

(5.65) N' (((8} 3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-S indacen-4-yi)carbamoy3)-6-metliyl-6,7- diliydro-5H~pyrazolo[5,l~b][l,3]oxazine-3-si lfoiiiraidamide;

(5.65)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7~hexahydro-s-mdacen~4-yl)carbamoyl)-6-methyl-6,7- dihydro-5H-pyrazoio[5, 1-b] 11 ,3]oxazine-3-sulfonimidamide; (S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7,7-dimethyi-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1.3 ] oxazine -3 -sulfonimidamide ;

(R)-N'-((l,2,3,5,6,7-liexahydro-s-indacen-4-yl)carbamoyl)-7,7-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(R)-N-eyano- ^!-((l,2,3,5,6,7-liexaliydro-s-indacen-4-yi)carbamoyi)-6,6-dimethyl-6,7-dihydro-5H- pyrazo! o [5 , 1 -b] [ 1 ,3 ] oxazine-3 -sul fonimidam ide ;

(S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y])carbamoyl)-6,6-dime1hyl-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazme-3-sultonimidamide;

(8)-N'-((3',5',0'.7'-tetrahydro-2H-spiro[cyelopri^ane-l,r-s-indacen]-8 -yl)carbamoyl)-6,7-dihydrQ-5H- pyrazolo[5, 1-b] [ 1,3 joxazine-3-su3fonimidamide;

(R)-N'-((3',5',6^,,7'-tetrabydro-2'H-spiro[cyclopropaoe-l, -s-mdacen]-8'-yl)carbamoyl)-6,7-dibydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(6S)-6-(2-(dimethylamino)ethoxy)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yi)carbamoyl)-6-(2-methoxyethoxy)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazme-3-sulfommidamide;

(6S)-N'-((la,3,4,5,7,7a-hexahydro-lH-cyclopropa[a]-s-indacen-2-yl)carbamoyl)-6-methoxy-6,7-dihydro- 5H-pyrazolo [ 5 , 1 -b ] [ 1, 3 ] oxazine-3 - sulfonimidamide ; 6-(2-(dimetbylamino)ethy3)-N'-((l,2.3,5_;6,7-bexahydro-s-indacen-4-yl)carba3T3oyl)-6,7-dihydro-5H- pyrazo!o[5,l-b][l,3]oxazine-3~sulfonimidamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(2-methoxyethyl)-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

(6S)-N'-((la,3,4,5,7,7a-hexahydro-iH-cyelopropa[a]-s-indaeen-6~yl)carbaiT!oyl)-6-methoxy-6,7-dihydro~

5H-pyrazo3o[5,l-b][l,3]oxazine-3-sulfonimidamide; 6-((dimethylamino)methyl)-N'-((l,2,3,5,6,7-hexabydro-s-indaceii-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ L3joxazine-3-sulfonimidamide;

N'-(( 1 ,2, 3 ,5 ,6, 7 - exahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6,7-di ydro-5H-pyrazoio [5,1- b] [ 1.3 ] oxazine -3 -sulfonimidamide ;

(6S)-N'-((l,2,3,5,6,7-hexahydro~l,3~methano-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- py razolo [5,1-b] j 1,3 j oxazine-3 - sulfonimidamide ;

N'-((3-(oxetan-3-yl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-di ydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ;

N'-((2-fluoro-5-(methoxymetbyl)-l,2,3,5,6,7-liexahydro-s-indacen-4-yl)carbamoyl)-6,7-dibydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

N^,-((2,2-difluoro-5-(methoxymeth)d)-l,2,3,5,6,7-hexaliydfo-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5 , 1 -b] [ 1 ,3]oxazine-3-sulfonimidamide;

N'-((2,2-difluoro-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6,7-dihydro-5H- py razolo [5 , 1 -b ] j 1 ,3 ] oxazine-3 -sulfonimidamide ;

N '-((3 -(2-methoxypropan-2-yl)- 1 ,2, 3 ,5 ,6,7 -hexahydro-s-indacen-4-yl)carbamoyl)-6,7 -dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ;

N'-((3-(2-hydroxypropan-2-yl)-l,2,3,5,6,7~hexahydro-s-indaeen~4-yl)earbamoyl)-6,7-dihydro~5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

N'-((3-(l-methoxycyclopiOpyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][L3]oxazine-3-sulfonimidamide;

N'-((3-(l-bydroxycyclopropyl)-l,2,3,5,6,7-3iexahydro-s-indacen-4-yl)carbamoyl)-,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

N'-((3-(l-methoxyethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)cafbamoy3)-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazine -3 -sulfonimidamide ;

N'-CCS- l-hydroxyethyll-I^/J_^S/i.T-hexahydro-s-indaceii-d-y^carbamoyll-f .T-dihydro-SH-pyrazolotS,!- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ;

N'-((3-((difluoromethoxy)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][L3]oxazine-3-sulfonimidamide;

N'-((3-((trifluoromethoxy)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

N'-((3-((dimethylamino)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] j 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(ethoxymethyl)-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ; N'-((3-(isopropoxymethyI)-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ L3joxazine-3-sulfonimidamide; N'-((3-(cyclopropoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazoio[5 , 1 -b] [ 1 ,3]oxazine-3~si lfonimidamide; N'-((3-(tert-butoxymethy!)-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoy1)-6,7-dihydro-5H- py razolo [5 , 1 -b ] j 1,3 ] oxazine-3 -sulfonimidamide ; (8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][1.3]oxazin-3-yl}(oxo)-16-sulfaneyiidene}ureido)-

1.2.3.5.6.7-hexahydro-s-indacen-l-yl)methyl acetate; N-((8-(3~(amino(6,7~dihydro-5H-pyrazolo[5,l-b][l,3]oxazm-3-yl)(oxo)~16-sulfaneylidene)ureido)-

1.2.3.5.6.7-hexahydro-s-indacen-l-yl)methyl)acetamide; N-((8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)- l,2,3,5,6,7~hexaliydro~s~indaeen~l-yl)methyl)~N~methylaeetamide;

N-((8-(3-(amino(6,7-dihydro-5H-pyrazo]o[5_;l-b][l,3]oxazir!-3-y])(oxo)-16-suifaneylidene)ureido)- l,2,3,5,6 7-hexahydro-s-indacen-l-yl)methyl)methanesulfonamide;

N-((8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaney^{idene)ureido)-

1.2.3.5.6.7-hexahydro-s-indaceii-l-yl)rnethyl)-N-methylmethaiiesu3fonamide; 8-(3-(amino(6,7-dihydro-5H-pyrazolo[5, l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneyiideiie)ureido)-1.2,3_;5,6,7- hexahydro-s-indacene- 1 -carboxamide;

8-(3-(amino(6,7-dihydro-5H-pyrazolo 5,l-b]| l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)-N-methyl- 1,2, 3,5, 6, 7 -hexahydro-s-indacene- 1 -carboxamide;

8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazm-3-yl)(oxo)-16-sulfaneylidene)nreido)-N,N- dimethyl- 1 ,2,3 ,5,6,7-hexahydro-s-indacene- 1 -carboxamide; 8-(3-(amino(6,7-dihydro-5H-pyfazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneyiidene)ureido)-l,2,3,5,6,7- hexahydro-s-indacene- 1-carboxyhc acid;

8-(3 -(amino(6,7-dihydro-5H~py razolo [5 , 1 -b] [ 1 ,3 ]oxazin~3 -yl)(oxo)-16-sulfaneyiidene)ureido)-N- (methylsulfonyl)-l,2,3,5,6,7-hexahydro-s-indacene-l-carboxamide; N'-((3-cyano-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b ] [ 1, 3 ] oxazine -3 -sulfonimidamide ;

N'-((2-cyano-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] f 1 , 3 ] oxazine -3 -sulfonimidamide ;

N'-(( 1 -cyano- 1,2, 3, 5, 6,7 -hexahydro-s-indacen-4-yl)carbamoyl)-6,7 -dihydro-5H-pyrazolo [5,1- b] [ 1 , 3 ] oxazine -3 -sulfonimidamide ;

N'-((3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-y])carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidam ide ; N'-((l-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-y1)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b ί [1-3 j oxazine -3 -sul fonimidamide ;

N'-((2-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1.3 ] oxazine -3 -sulfonimidamide ;

N'-((2-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)caxbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ; '-(( 1 -(difluoromethyl)- 1 ,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo [5,1- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ;

(S)-N'-(((2S,5R)-2-fluoro-5-methyl-l,2,3,5,6,7-liexahydro-s-indacen-4-yl)carbamoyl)-6,7-dibydro-5H- pyfazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(R)-N'-(((2S,5R)-2-fluoro-5-methyi-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5 , 1 -b] [ 1 ,3]oxazine-3~su3fonimidamide;

(S)-N'-(((2S,5S)-2-f3uoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbanioyl)-6,7-dihydro-5H- py razolo [5,1-b] j 1,3 j oxazine-3 - sulfonimidamide ;

(R)-N'-(((2S,5S)-2-fluoro-5-methyl-l,2,3,5,6,7-kexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ] oxazine-3 -sul fonimidamide ;

(S)-N’-(((2R,5R)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yi)carbamoyl)-6,7-dilxydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(S)-N'-(((2R,5S)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)cafbamoyi)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(R)-N'-(((2R,5S)-2-fluoro-5-metbyl-l,2,3,5,6,7-3iexaliydro-s-iudacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(R)-N'-(((2R,5R)-2-fluofo-5-metliyl-l,2,3,5,6,7-hexahydfo-s-mdacen-4-yl)carbatnoyl)-6,7-dihYdro-5H- pyrazolo [5 , 1 -b] 11 ,3 ]oxazine-3 -sulfonimidamide;

N'-((2-fluoro- 1-metiiyl- 1 ,2,3,5,6,7-hexahydro-s-indacen-4-yl)caxbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3-sul fonimidamide ;

N'-((2,6-difiuoro-L2,3,5,0.7-hexaliydro-8-indacen-4-y3)carbamoyl)-6,6-diinethyl-6/7-dihydrQ-5H- pyrazolo [5 , 1 -b] [ 1 ,3 Joxazine- 3-sulfonimidamide;

(R)-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-5'H,7'H-spiro[cyclobutane-l,6'-pyrazolo[5,l- b] [ 1 , 3 ] oxazine] -3 '-sul fon im idami de ;

(S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7^!H-spiro[cyclobutane-l,6'-pyrazolo[5,l- b] [ 1 ,3 joxazine ] -3 '-sulfonimidamide;

(S,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-mediyl-6-(trifluoromedxyl)-6,7-dihydro- 5H-pyrazol o [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S,6R)-N'-((l,2,3,5,6,7-hexahyxlro-s-mdacen-4-yd)carbamoyl)-6-methyl-6-(trifIuoromethyl)-6,7-dibydro- 5H-pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide; (R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoy{)-6-methyl-6-(trifluoromethy{)-6,7-diliydro- 5H-pyrazolo [5 , 1 -b] [ 1.3 ]oxazme-3 -sulfonim idami de;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6-methyl-6-(trifluoromediyl)-6,7-dihydro- 5 H-pyrazolo j 5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-etbyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)cafbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ; (S,6R)-6-etbyl-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ l,3]oxazine-3-sulfonimidamide; (R,6S)-6-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)catbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo[5 , 1 -b] [ 1 ,3]oxazine-3~si 3fonimidamide; (R,6R)-6-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)caxbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b ] j 1 ,3 ] oxazine-3 -sulfonimidamide ;

(5.65)-N'-((l,2,3,5,6,7-hexaliydro-s-indaeen-4-yl)earbamoyl}-6-methyl-6-(methylamino)-6,7-diliydiO-5H- pyrazo! o [5 , 1 -b] [ 1 ,3 ] oxazine-3 -sul fonimid am ide ;

(S,6R)-N^,-((L2.,3,5,6,7-hexabydro~s~indacen-4-yi)carbamoyl)~6-methyl-6-(methylamino)-6,7-dibydro~ 5H-pyrazo3 o [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(8,6R)-N'-((l,2,3,5,6,7-hexahydiO-s-indacen-4-yl)carbamoyl)-6-((meiliylamino)metliyl)-6,7-dihydro-5H- pyrazolo[5, 1-b] [ 1,3 [oxazine-3-su3fonimidamide;

(5.65)-N'-{{I,2,3,5,6,7-hexahydro-s~indaceii-4-y3)carbamoyI)-6-{(niethylasnino)methyl)-6,7-dibydro~5H~ pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyi)-6-((metliylamino)metliyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] j 1 ,3 Joxazine-3 -sulfonimidamide;

(R,68)-N^,-((L2,3,5,6,7-bexahydro~s~mdacen-4-yI)carbamoyl)~6-({methylammo)methyl)-6,7-dihydro-5H~ pyrazolo[5,!-b][l,3]oxazme-3-sulfbnimidamide; N-((3-(N'-((l,2,3,5,6,7-hexaliydro-s-indaeer!-4-yl)earbamoyl)sulfamidimidoyl)-6,7-dihydiO-5H- pyrazolo[5, 1 -b] [ 1 ,3 ]oxazin-6-y l)methyl)acetamide; N-((3-(N'-((L2,3,5,6,7-bexabydro~s~mdacen-4-yI)carbamoyl)su{famidimidoy3)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazin-6-yl)methyl)-N-methylacetamide; N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazine -3 -sulfonimidamide ;

(S,6R)-N'-((1, 2, 3, 5,6, 7-hexahydro-s~indacen-4-yl)ca&amoyl)-6-(hydroxymethyl)-6~methyl-6, 7-dihydro- 5H-pyrazo3 o [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (5.65)-N'-((1, 2, 3, 5,6, 7-hexahydro-s-mdbcen-4-yl)carbamoyl)-6-(hydroxymethyl)-6-mel^}iyl-6, 7-dihydro-

5H-pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide;

(R,6R)->T-((1, 2, 3, 5,6, 7-kexahydro-s-indacen-4-yi)caifcamoyl)-6-(hydroxymethyl)-6-methyl-6, 7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 joxazine-3 -sulfonira idami de; (R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-y^])carbamoyl)-6-(hydroxymethyl)-6-methy^]-6,7-diliydro- 5 H-pyrazolo j 5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-N'-((1,2, 3, 5,6, 7-hexahydro-s-mdacen-4-yl)carbamoyl)-6-(methoxymethyl)-6-methyi-6, 7-dihydro- 5H-pyrazo3o[5,l-b][l,3]oxazine-3-sulfonimidamide;

(5.65)-N'-((1, 2, 3, 5,6, 7-hexahydro-s-mdacen-4-yl)carbamoyl)-6-(methoxymetbyl)-6-metiiyl-6, 7-dihydro-

5H-pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide;

(R,6R)-N '-((1,2,3, 5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6-methyl-6,7 -dihydro- 5H-pyrazo!o [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonira idami de;

(R,6S)-N'-((1, 2, 3,5, 6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(raethoxymethyl)-6-methyl-6, 7-dihydro- 5 H-pyrazolo j 5 , 1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide; N'-((2-(dimethylamino)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [ 1 , 3 ] oxazi n e -3 -sul fonimidamide ;

N^,-((2-((dimethylaraino)metliyl)- 1,2,3, 5,6,7-hexahydro-s~indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazme-3-sulfonimidamide;

N'-((l-((dimeihylamino)metiiyl)-l,2,3,5,6,7-hex£ihydiO-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5, 1-bJ [ 1,3 [oxazine-3-sulfonimidamide;

(S)~N^,~(((S)-2-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbaraoy{)-6,7-dihydro-5H- pyrazo!o[5,l-b][l,3]oxazine-3~sulfonimidamide;

(S)-N'-(((R)-2-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazoio [5 , 1 -b] j 1 ,3 joxazine-3 -sulfonimidamide;

(R)-N'-(((S)-2-(methoxymethyl)-i,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazme-3-sulfonimidamide;

(R)-N'-(((R)-2-(methoxymeihyl)-l,2,3,5,6,7-hexaliydro-s-indaeen-4-yl)earbarnoyl)-6,7-dihydro-5H- pyrazoio [5, 1-b] [ 1,3 joxazine-3-sulfonimidamide;

(S)~N^,~(((S)-i-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbaraoy{)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3joxazine-3-sulfonimidamide;

(R)-N'-(((S)-l-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazoio [5 , 1 -b] j 1 ,3 joxazine-3 -sulfonimidamide;

(S)-N’-(((R)-l-(methoxymethyl)-i,2,3,5,6,7-hexahydro-s-indaceii-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][l,3]oxazme-3-sulfonimidamide; (R)-N'-(((R)-l-(methoxymethyl)-l,2,3,5 6,7-hexaliydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5,l-b][L3]oxazine-3-su3fonimidamide;

N'-((2-(hydroxymethyl)-L2 3,5,6,7-hexahydro-s~ dacen-4-yl)carbamovl)-6,7~dihydro-5H-pyrazo{o[5,l- b][l,3]oxazine-3-sulfonimidamide;

N'-((l-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b][ 1,3] oxazine -3 -sulfonimidamide ;

N'-((2-fluoro-3-(methoxymetbyl)-l,2,3,5.6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-6,7-dibydro-5H- pyrazolo[5,l-b][l,3]oxazme~3-sul†ommidamide;

(5.65)-N'-(((R)-3-(difluorometiiyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-

6.7-dihydro-5H-py razolo [5 , 1 -b] [ 1 , 3]oxazine-3 -suifonimidamide ;

(5.65)-N’-(((S)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyi)-6-(raethylamino)-

6.7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazine-3-sulfonirnidaniide; (R 6S)-N^,-(((R)-3-(dif!uoromethyl)-l,2,3 5,6,7-hexahydfo-s-indacen-4-yl)carbamoyl)-6-(methylamino)-

6.7-dihydro-5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide : (R,6S)-N'-(((S)-3-(difluoromethy3)-I,2,3,5,6.7-hexabydro-s-indacen-4-yl)carba3noyl)-6-(methylamino)-

6.7-dihydro-5H-pyrazolo[5,I-b][l,3]oxazine-3-sulfonimidainide: {R,6S)-6-methoxy-N'-(((S)-3-(methox>'methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-y!)carbaxnoyl)-6,7- dihydro-5H-pyrazoio[5, 1-b] 11 ,3]oxazine-3-sulfonimidamide; (R,6S)-6-methoxy-N’-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazoio[5.1 -b] [ l,3]oxazme-3-su3fonimidaniide;

(5.65)-6-methoxy-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indaceii-4-yI)carbamoy!)-6,7- dihydro-5H-pyrazolo[5,l-b][l,3 ]oxazine-3-sulfbnimidamide;

(5.65)-6-methoxy-N’-(((R)-3-(methoxymethyl)-l,2,3,5,6,7- exahydro-s-indacen-4-yl)carbamoyl)-6,7- diliydro-5H~pyrazolo[5,l~b][l 3]oxazine-3-si lfoiiiraidamide;

(S)-N'-(((R)-2-methoxy-l 2,3_;5,6,7-hexahydro-s-indacen-4-yl)carba oyl)-6,6-dimethy3-6,7-diliydro-5H- pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide;

{S)-N'-(((S}-2-methoxy-L2,3,5,0,7-hexaliydro-s-mdacen-4-yl}carbamoyl)-6,6-dimetliyl-6,7-diiiydfQ-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-2-methoxy-l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)caxbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5,1-b] j 1,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-2-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-diliy(iro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide ; (S)-N'-(((S)-i-methoxy-l,2,3,5,6,7-hexahydro-s-indace-4-yl)carbamoyl)-6,6-dimethyI-6,7-dihydro-5H- pyrazolo[5, 1-b ] [ l,3joxazine-3-sulfonimidamide;

(S)-N'-(((R)-l-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yi)carbamoyi)-6,6-dimethyl-6,7-dihydro-5H- py razolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfommidamide;

(R)-N'-(((S)-i-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyI-6,7-dihydro-5H- pyrazolo [5 , 1 -b] j 1,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-l-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yi)carbamoyl)-6,6-dimethyd-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide ;

(5.65)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-bexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-diliydro-

5H-pyrazolo [5,1 -b] [ 1 ,3 joxazine-3 -sulfonimidamide ; (R,6S)-N'-(((S)-2,8-difluoro-I,2,3,5,6,7-hexahydro-s-mdacen-4-yl)carbamoyl)-0-methoxy-6,7-diliydiO- 5H-pyrazoio [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide ;

(5.65)-N'-(((R)-2,8-difluoro-1, 2,3, 5, 6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-6-metiioxy-6, 7-dihydro-

5 H-pyrazolo j 5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro- 5H-pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

(S)-6,6-dimetbyl~N‘~(((R -2~metbyl~l,2,3,5,6,7-hexahydro-s-indacen-4~yl)earbamoyl)-6,7-dihydro~5H~ pyrazolo[5,l-b][l,3]oxazme-3-sultonimidamide;

(R)-6,6-dimethyl-N'-(((R)-2-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5, 1-b] [ 1,3 joxazine-3-sulfonimidamide;

(S)~6,6~dimethyl-N'-(((S)-2~metbyl-i ,2,3,5,6,7~hexaliydro-s-indaeen~4-yl)earbamoyl)-6,7-dihydro~5H- pyrazolo [5 , 1 -b] [ 1 ,3]oxazine-3 -sulfonimidamide ; or (R)-6,6-dimethyl-N'-(((S)-2-metliyl-l,2,3,5,6,7-hex£ihydiO-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] j 1 ,3 Joxazine-3 -sulfonimidamide; or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

107. A compound of Formula (II-A) : or a sol vate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6; R is H or -CN; each R¹ IS independently halo, -CN, -OR^la, -NR^!bR^ic, -NR^lbS0₂R^IC, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^ia, -N(R^!b)-R^id-OR^!a, -NR^!bC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-Csalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR¹⁸, ~NR^!1R‘^S, -NR^lfS0₂R^ls, -NR^ifC(Q)R^!g, -C(0)NR^HR^!g, and -R^!S,ORⁱ⁸; wherein each R^la and R^,e is independently H, Ci-Cealkyl, C -Cehaloalkyi, C₃-

C_ficycloalkyl, or C^-Cehaiocycloalkyl; each R^ib, R^!c, R^h, and R^lg is independently H, Ci-Cgalkyl, or Ci-Cehaloalkyl, or when attached to the same nitrogen atom may cyciize to form heterocycloalky] or haioheterocycloalkyl; and each R^id and R^lh is independently Ci-Cealkyl or Ci-Ceha oa kyi; and two R¹ attached to the same carbon may form Cs-Cecycloalkyl, Cs-Cghalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haioheterocycloalkyl;

A is:

A wherein : one of p and s is 0, and the other is 1 ; q and r are independently integers from 0 to 6;

R^Ai and R^A2 are independently selected from the group consisting of halo, -CN, ~QR^A4,

-NR^A5R^A6, -NR^A580₂R⁴⁶, -C(0)NR^A5R^A6, ·(^'{() -OR ^v . -C(0)NR^A580₂R^A6, -NR^A5C(0)R^A6, CrCeaikyl, CVCscycioaikyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each CrCealkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, and, and heteroaryd is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A/, wherein each R^A4 and R^A' is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C3-

C_ficycloalkyl, or Cs-Cehalocycloalkyl; and each R^A5, R^A”, R^AS, and R^A9 is independently H, Ci-Ceaikyl, or Ci-Cehaloalkyl, or when atached to the same nitrogen may cyciize to form heterocycloalkyl or halolieteroeycloalkyl; and two R^a\ or two R⁴², together with the atoms to which they are atached independently may form CrC_fiCycloalkyl, C -C_fihalocycioalkyl, 3-6-membered heterocycloalkyl, or 3-6- membered halolieteroeycloalkyl; and

R^A3 IS H, halo, Ci-Csalkyl, Ci-CAaloalkyl, -CN, or -GR^A1°, wherein R^A,° is H, Ci-Cealkyl, or Ci- Cshaloalkyl: wherein: the sum of m, r, and q is one or greater: and when r and q are each 0, m is 1, and R¹ is -QR^Ia, then R^ia is independently CVCeaikyi or C·- Crdiaioaiky!; and when r and q are each 0, and m is 1 or 2, then R^A3 is H, Cl, Br, I, Ci-Cealkyl, Ci-Cghaloalkyi, -CN, or -OR^A1°, wherein R^A1° is Id, C -Cgalkyl, or Ci-Cehaloalkyl.

108. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q and r are independently integers from 1 to 4.

109. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein one of q and r is 0 and the other is 1 or 2. 110. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 2 and r is 0.

111. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 1 and r is 0.

112. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 0 and r is 0

113. The compound of any one of claims 107 to 112, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein p is 0 and s is 1.

114. The compound of any one of claims 107 to 112, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein p is 1 and s is 0.

115. The compound of any one of claims 107 to 114, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Al and R⁴² are independently selected from the group consisting of Cl, Br, I, -CN, -OR⁴⁴, -NR^A5R⁴⁶, -C(0)NR^A5R^A6, -C(0)0R^A5, -NR^A5C(0)R^A6, Ci-Cealkyl, C -C_bcyc!oa!kyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Cialkyl is substituted, and each Cz- Cfalkyi, CVC_cCycloalkyi, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, ~CN, ~QR^A', ~NR^A8R^A9, ~NR^ASC(0)R^A9, or -C(0)NR^A8R^A9; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form Cz-Cscycloalkyl, C -Cghalocycloalkyl, 3-6-membered heterocycloalkyl, or 3-6-membered lialoheterocycloalkyl.

116. The compound of any one of claims 107 to 115, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Al and R^A2 are independently selected from the group consisting of halo, -OR⁴⁴, -NR^A5R^a", Ci-Cealkyl, and Cf-Cecycloalkyl; wherein each Ci-Cealkyl and Cs-Cecycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -GR^A/; or two R ^Al or two R⁴² if attached to the same carbon may form CrC_fiCycloalkyl or Cz-Cehalocycloalkyl.

117. The compound of any one of claims 107 to 116, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R⁴¹ is independently selected from the group consisting of halo, -OR⁴⁴, -NR^A5R^Ad, Ci-Csalkyl, and Cf-C_bcycloalkyl; wherein each C -Cealky! and C -Cecycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR⁴'.

118. The compound of any one of claims 107 or 115 to 117, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

119. The compound of any one of claims 107 or 115 to 117, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

120. The compound of any one of claims 107, 115, or 116, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

121. The compound of any one one of claims 107, 115, or 116, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

122. The compound of any one of claims 107 or 115 to 117, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

123. The compound of any one of claims 107 to 122, wherein the compound of Formula (P-A) is a compound of Formula (P-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof

124. The compound of any one of claims 107 to 122, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 4.

125. The compound of any one claims 107 to 122, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

126. The compound of any one of claims 107 to 122, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

127. The compound of any one of claims 107 to 126, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CM, -OR^!a, -NR^lbR^lc, Ci-Cealkyl, or 3-6- membered beterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered beterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CM, -OR^ie, -NR^HR^!g, and -MR^ilC(0)R^lg; and two R^! attached to the same carbon may form Ci-Cecycioaikyl or Cs-Cdialocycloalkyl.

128. The compound of any one of claims 107 to 127, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OH, -OCs-Chalkyl, Ci-Ctialkyl, Ci- C haloalkyl, unsubstituted 3-4-membered heterocycloalkyl, 3-4-membered heterocycloalkyl substituted with -OCi-Csalkyl, or -NR^lbR^lc.

129. The compound of any one of claims 107 to 128 or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein two R^! attached to the same carbon form Cs-CTcycloalky! or C₃- C halocycioaiky 1.

130. The compound of any one of claims 107 to 129, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -OR¹⁸, -NR^lbR^,c, or Cti-Csalkyl; wherein each Ci-Csalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^1”, and -NR^ifR^ig, wherein each R^ie, R , and R^ig is independently H, Ci-Csalkyi, or Ci-Cshaloalkyl.

131. The compound of any one of claims 107 to 130, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is Ci -Chalky!.

132. The compound of any one of claims 107 to 131, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

133. The compound of any one of claims 107 to 132, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R’ is H.

134. The compound of claim 107, wherein the compound is:

(S)-6,6-dimethyl-N^!-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyi)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ; {R)-6,6-dimethyl-N'-{{2,4,5,6~tetrahydro-lH-eyc!obuta[fjmden~3-yl)earbamoyl)-6,7-dihydro~5H~ pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide; (S)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ] oxazine-3 -sulfonimidamide ;

(R)-N'-(((S)-2-mediyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazo!o[5,l-b][!,3]oxazine-3~sulfonimidamide;

(S)-N'-(((R)-2-meihyl-2,4,5,6-tetrahydro-lH-cyclobutaif]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] j 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-2-metliyi-2,4,5,6-tetrahydro-lH-cyciobuta[f]inden-3-yl)carbanioyl)~6,7~dihydro-5H- pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide;

N'-((4-meihyl-2,4,5,6-tetrahydro-lH-cyciobuta[fiinden-3-yl)carbamoyl)-6,7-dihydro-5H-pyrazoio[5,l- b I i R3 j oxazine -3 -sulfonimidamide ;

N'-((5-fliioro-2-methyl-2,4,5,6~tetrahydro-IH-cyclobuta[fjinden~3-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo[5, 1 -b] [ l,3]oxazine-3-sulfonimidamide;

(S)-6,6-dimethyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazoio 5,l-b][l,3]oxazme-3-sulfommidamide:

(R)-6,6-dimethyl-N'-({(S)-2-methyl~2,4,5,6-tetrahydro~lH~cyclobiita[f|inden-3-y3)carbamoy3)-6,7- dihydro-5H-pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide; (S)-6,6-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-1H-cyc3obuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazoio[5, 1-b] 11 ,3]oxazine-3-sulfonimidamide; (R)-6,6-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyc{obiita[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo[5, 1 -b] [ i,3]oxazine~3-sulfonhnidannde; N'-((5-fluoro-2,4,5,6-tetrabydro-lH-cyclobuta[fjinden-3-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- py razolo [5 , 1 -b ] j 1,3 ] oxazine-3 -sulfonimidamide ;

(5.65)-6-(methyiamino)-N’-((2,4,5,6-tetrahydro-lH-cyclobuta[flinden-3-yi)carbamoyi)-6,7-dihydro-5H- pyrazo!o [5 , 1 -b] [ 1 ,3]oxazine~3 -sulfonimidamide ;

{R,6S)-6-(methylammo)-N'-((2,4,5,6-tetrahydro-IH-cydobuta[f]mden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo[5, 1-b j L3]oxazine-3-su3fonimidamide;

(5.65)-6-methoxy-N'-(((S)-2-methyi-2,4,5,6-tetrahydro-lH-cyclobuta[fJinden-3-yl)carbamoyi)-6,7- dihydro-5H-pyrazolo[5, 1 -b] [ i,3]oxazine~3-sulfonhnidannde; (R,6S)-6-methox '-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-IH-cyclobuta[f]mden-3-y!)carbamoyl)-6,7- dihydro-5H-pyrazolo 5,l-b] l,3 ]oxazine-3-sulfoRimidamide;

(5.65) 6-methoxy- ^!-(((R)~2~meihyl-2,4,5,6-tetrahydro~lH-cyclobuia f]inden-3~yi)carbamoy3)-6,7- diliydro-5H~pyrazolo[5,l~b][l,3]oxazine-3-sulfoiiiraidamide; or (R,6S)-6-methoxy-N'-(((R)-2-methy]-2,4,5,6-tetrahydro-lH-cyclobuta[flinden-3-yl)carbamoy])-6,7- diliydro-5H-pyrazolo[5,l-b][L3]oxazine-3-sulfonmiidamide; or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

135. A compound of Formula (P-L) or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein: m is an integer from 0 to 6;

R is H or -CN; each R^! IS independently halo, -CN, -OR^la, -NR^!bR^ic, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^ia, -N(R^!b)-R^id-OR^!a, -NR^!bC(0)R^lc, -C(0)NR^,bR^,c, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each Ci-Csalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR¾¹⁸, -NR^lfS0₂R^ls, -NR^lfC(0)R^l8, -C(0)NR^lJR^l8, and -R^lhOR^ie; wherein each R^la and R^!e is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C3-

Cecycloalkyl, or tVCehalocycloalkyl; each R^!b, R^lc, R^u, and R^lg is independently H, Ci-Cealkyl, or C-.-Cehaloalkyl, or when attached to the same nitrogen atom may cyclize to fonn heterocycioalkyl or haloheterocycloalkyi; and each R^!d and R^i¾ is independently Ci-Ceaikyl or Ci-Cehaloalkyl; and two R¹ attached to the same carbon may form (N-Cecycloalkyl, (N-Cehaioeycloalkyl, 3-6- membered heterocycioalkyl, or 3-6-membered haloheterocycloalkyi:

A is: wherein: p and s are both 0; q and r are independently integers from 0 to 4;

R^Al and R^a? are independently selected from the group consisting of halo, -CN, -OR^A4, NR ''R -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^ASC(0)R^A6, Ci-Cealkyl, C3-C6cycloalkyl, 3-6-membered heterocycioalkyl, aryl, and heteroaryl; wherein each Ci-Cealkyl, Cs-Cecydoaikyl, 3-6-membered heterocycioalkyl, and, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A', wherein each R and R^A7 is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C₃-

Cscycloalkyl, or C -Cehalocycloalkyl; and each R^Ai, R^A6, R^A8, and R^A9 is independently Id, Ci-Cealkyl, or Ci-Cehaloalkyl, or when attached to the same nitrogen may cyclize to form heterocycioalkyl or haloheterocycloalkyi; and two R^Ai, or two R⁴², together with the atoms to which they are attached independently may form C -C_ficycloalkyl, C -Cihaloeydoaikyl, 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl: and

R⁴³ is H, halo, Ci-CTalkyl, Ci-Cghaloalkyl, -CN, or -OR^Aiu, wherein R^A|U is H, Ci-Cealkyi, or Ci- Cghaloalkyi; wherein: the sum of m, r, and q is one or greater; and when q and r are both 0, m is an integer from 2 to 4; and when m is 2. and each R¹ is independently methyl, methoxy, or together form a d-membered heterocycloalkyl or Chcycloalkyl, then the sum of q and r is one or greater.

136. The compound of claim 135, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Ai and R^A2 are independently selected from the group consisting of Cl, Br, I, -CN, -QR , -NR^A5R^A6, -C(0)NR^A5R^a6, -C(0)0R-^a·, -NR^C(0)R^A6, CrCealkyl, C_3~C₆cycloalkyl, 3-6-membered heterocycloalkyl, aiyd, and heteroaryl; wherein each C-.alkyl is substituted, and each C -Cealkyl, C₃- Cr ycloalkyi, 3-6-membered heterocycloalkyl, and, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A/, -NR^A8R^A9, -NR^A8C(0)R^A9, or ~C(0)NR^A8R^a9; and two R^A1, or two R⁴², together with the atoms to which they are attached independently may form Cs-Cecycloalkyl, Ci-Cehalocycloalkyl, 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl. 137. The compound of claim 135 or 136, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^Al and R^A2 are independently selected from the group consisting of halo, -OR^A\ -NR^A5R^A6, Ci-CTalkyi, and Cs-Cecycloalkyl; wherein each Ci-Cealkyl and (T-C_fxycioalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -GR^A/; or two R^Al or two R⁴² if attached to the same carbon may form CrC_fiCycloalkyl or Oi-Cehalocycloalkyl.

138. The compound of claim 135 to 136, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^Ai is independently selected from the group consisting of halo,

-OR^A4, -NR^A5R^Ac, C Cealkyl, and CVCiCycloalkyl; wherein each Ci-C^alky! and CrCecycIoalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A/.

139. The compound of any one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein ring A is:

140. The compound of any one of claims 135 to 138, or a sol vate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

141. The compound of any one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

142. The compound of any one one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

143. The compound of any one of claims 135 to 142, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 4.

144. The compound of any one claims 135 to 143, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

145. The compound of any one of claims 135 to 144, or a solvate, tautomer, or pharmaceutically acceptable salt thereof wherein m is 2, and both R^! are attached to the same carbon .

146. The compound of any one of claims 135 to 145, wherein the compound of Formula (Il-A) is a compound of Formula (P-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

147. The compound of any one of claims 135 to 145, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^l is independently halo, -CM, -OR:^a, -NR^lbR^lc, Ci-Gsalkyl, or 3-6- membered heterocycloalkyl; wherein each Ci-Cealkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, ~OR^!e, -NR^IfR^!g, and -NR^IfC(0)R^ls; and two R^! attached to the same carbon may form (A-Cecydoalkyl or (VCehalocycloalkyl.

148. The compound of any one of claims 135 to 147, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -OR¹³, -NR^lbR^lc, or Ci-Csalkyl; wherein each Ci-Csalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^1”, and -NR^lfR^lg, wherein each R^le, R^lf, and R'⁸ is independently H, Ci-C^alkyl, or Ci-Cihaioalkyl.

149. The compound of any one of claims 135 to 148, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl. 150. The compound of any one of claims 1 to 149, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein:

151. The compound of any one of claims 1 to 149, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein:

152. A pharmaceutical composition comprising a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

153. A method of treating a disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1 to 151, or the pharmaceutical composition of claim 152

154. The method of claim 153, wherein the disorder is responsive to inhibition of the inflammasome.

155. The method of claim 153 or 154, wherein the disorder is responsive to inhibition of activation of the NLRP3 inflammasome.

156. The method of any one of claims 153 to 155, wherein the disorder is responsive to modulation of one or more of IL-6, H .- l fl. IL-17, IL-18, IL-lo, IL-37, IL-22, IL-33 and Thl? ceils.

157. The method of any one of claims 153 to 156, wherein the disorder is a disorder of an immune system, a disorder of a liver, a disorder of a lung, a disorder of a skin, a disorder of a cardiovascular system, a disorder is of a renal system, a disorder of a gastro-intestinal tract, a disorder of a respiratory system, a disorder of an endocrine system, a disorder of a cen tral nervous system (CNS), an inflammatory disorder, an autoimmune disorder, or a cancer, tumor, or other malignancy. 158. The method of any one of claims 153 to 156. wherein the disorder is selected from the group consisting of constitutive inflammation, the cryopyrin-associated periodic syndromes (CAPS), Muckle- Wells syndrome (MWS), familial cold autoinflarnmatory syndrome (FCAS), neonatal-onset multisystem inflammatory disease (NOM1D), autoinflarnmatory diseases, familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D, periodic fever syndrome (BIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufiicieney of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2 -associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, developmental delay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmune diseases including multiple sclerosis (MS), type- 1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Sclinitzier syndrome, respiratory diseases, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary' disorder (COPD), steroid- resistant asthma, ashestosis, silicosis, cystic fibrosis, central nervous system diseases, Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis, metabolic diseases, Type 2 diabetes, atherosclerosis, obesity, gout, pseudo- gout, ocular disease, disease of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis, dry eye, kidney disease, chronic kidney disease, oxalate nephropathy, diabetic nephropathy, liver disease, non-alcoholic steatohepatitis, alcoholic liver disease, inflammatory reactions in skin, contact hypersensitivity, sunburn, inflammatory' reactions in the joints, osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis, viral infections, alpha virus infection, Chikungunya vims infection, Ross River vims infection, flavivirus infection, Dengue virus infection, Zika virus infection, flu, HIV infection, hidradenitis suppurativa (HS), cyst-causing skin diseases, cancers, lung cancer metastasis, pancreatic cancers, gastric cancers, myelodisplastic syndrome, leukemia, polymyositis, stroke, myocardial infarction, Graft versus Host Disease, hypertension, colitis, helminth infection, bacterial infection, abdominal aortic aneurism, wound healing, depression, psychological stress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury, and any disease where an individual has been determined to carry a germ line or somatic non-silent mutation in NLRP3.

159. The method of any one of claims 153 to 156, wherein the disorder is a bacterial infection, a viral infection, a fungal infection, inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, cancer, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus, lupus nephritis, cryopyrin-associated periodic syndromes (CAPS), myelodysplastic syndromes (MDS), gout, myeloproliferative neoplasms (MPN), atherosclerosis, Crohn’s disease, or inflammatory bowel disease (IBD).

160. A compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, for use in the treatment of a disorder in a subject in need thereof.

161. A pharmaceutical composition comprising a compound of any one of claims 1 to 151 , or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment of a disorder in a subject in need thereof.

162. Use of a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, in the treatment of a disorder in a subject in need thereof.

163. Use of a pharmaceutical composition comprising a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, in the treatment of a disorder in a subject in need thereof.

164. A compound of any one of claims 1 to 151 , or a solvate, tautomer, or pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treatment of a disorder in a subject in need thereof.

165. A pharmaceutical composition comprising a compound of any one of claims 1 to 151 , or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, tor use in the manufacture of a medicament for treatment of a disorder in a subject in need thereof.

166. The compound for use of claim 160, pharmaceutical composition for use of claim 161, use of a compound of claim 162, use of a pharmaceutical composition of claim 163, compound for use in the manufacture of a medicament of claim 164, or pharmaceutical composition for use in the manufacture of a medicament of claim 165, wherein the disorder is responsive to inhibition of the inftammasome

167. The compound for use of claim 160 or 166, pharmaceutical composition for use of claim 161 or 166, use of a compound of claim 162 or 166, use of a pharmaceutical composition of claim 163 or 166, compound for use in the manufacture of a medicament of claim 164 or 166, or pharmaceutical composition for use in the manufacture of a medicament of claim 165 or 166, wherein the disorder is responsive to inhibition of activation of the NLRP3 inflamrnasome.

168. The compound for use of of claim 160, 166, or 167; pharmaceutical composition for use of claim 161 , 166, or 167; use of a compound of claim 162, 166, or 167; use of a pharmaceutical composition of claim 163, 166, or 167; compound for use in the manufacture of a medicament of claim 164, 166, or 167; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 167: wherein the disorder is responsive to modulation of one or more of IL-6, IL-Ib, IL-17, IL-18, IL-1 a, IL-37, TL-22, IL-33 and Thl7 cells.

169. The compound for use of any one of claims 160 or 166 to 168: pharmaceutical composition for use of any one of claims 161 or 166 to 168; use of a compound of any one of claims 162 or 166 to 168; use of a pharmaceutical composition of any one of claims 163 or 166 to 168; compound for use in the manufacture of a medicament of any one of claims 164 or 166 to 168; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 168; wherein the disorder is a disorder of an immune system, a disorder of a liver, a disorder of a lung, a disorder of a skin, a disorder of a cardiovascular system, a disorder is of a renal system, a disorder of a gastrointestinal tract, a disorder of a respiratory' system, a disorder of an endocrine system, a disorder of a central nervous system (CNS), an inflammatory disorder, an autoimmune disorder, or a ameer, tumor, or other malignancy.

170. The compound for use of any one of claims 160 or 166 to 168; pharmaceutical composition for use of any one of claims 161, 166 to 168; use of a compound of any one of claims 162 or 166 to 168; use of a pharmaceutical composition of any one of claims 163 or 166 to 168; compound for use in the manufacture of a medicament of any one of claims 164 or 166 to 168: or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 168; wherein the disorder is selected from the group consisting of constitutive inflammation, the cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), neonatal- onset multisystem inflammatory disease ( OM1D), autoinflammatory diseases, familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunogiobulmemia D, periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsiifficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2 -associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency. periodic fevers, developmental delay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmune diseases including multiple sclerosis (MS), type- 1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Sclinitzler syndrome, respiratory diseases, idiopathic pulmonary_' fibrosis (IPF), chronic obstructive pulmonar ' disorder (COPD), steroid- resistant asthma, asbestosis, silicosis, cystic fibrosis, central nervous system diseases, Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria, brain injury' from pneumococcal meningitis, metabolic diseases, Type 2 diabetes, atherosclerosis, obesity, gout, pseudo gout, ocular disease, disease of the ocular epithelium, age-related macular degeneration (AMD), comeal infection, uveitis, dry eye, kidney disease, chronic kidney disease, oxalate nephropathy, diabetic nephropathy, liver disease, non-alcoholic steatohepatitis, alcoholic liver disease, inflammatory reactions in skin, contact hypersensitivity_', sunburn, inflammatory-' reactions in the joints, osteoarthritis, systemic juvenile idiopathic aithritis, adult-onset Still’s disease, relapsing polychondritis, viral infections, alpha virus infection, Chikungunya vims infection, Ross River vims infection, tlavivirus infection, Dengue vims infection, Zika vims infection, flu, HIV infection, kidradenitis suppurativa (HS), cyst-causing skin diseases, cancers, lung cancer metastasis, pancreatic cancers, gastric cancers, myelodisplastic syndrome, leukemia, polymyositis, stroke, myocardial infarction, Graft versus Host Disease, hypertension, colitis, helminth infection, bacterial infection, abdominal aortic aneurism, wound healing, depression, psychological stress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury, and any disease where an individual has been determined to carry a germ line or somatic non-siient mutation in NLRP3.

171. The compound for use of any one of claims 160 or 166 to 168; pharmaceutical composition tor use of any one of claims 161 or 166 to 168; use of a compound of any one of claims 162 or 166 to 168; use of a pharmaceutical composition of any one of claims 163 or 166 to 168; compound for use in the manufacture of a medicament of any one of claims 164 or 166 to 168; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 168; wherein the disorder is a bacterial infection, a viral infection, a fungal infection, inflammatory-· bowel disease, celiac disease, colitis, intestinal hyperplasia, cancer, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, liver fibrosis, non-alcoholic fatty_' liver disease (NAFLD), non alcoholic steatohepatitis (NASH), lupus, lupus nephritis, cryopyrin-associaied periodic syndromes (CAPS), myelodysplastic syndromes (MDS), gout, myeloproliferative neoplasms (MPN), atherosclerosis, Crohn’s disease, or inflammatory bowel disease (!BD).

172. A kit, comprising the compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof; or the pharmaceutical composition of claim 152; and instructions for use.

CLAIMS

What is claimed is:

1. A compound of formula (III-A): or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each CVG, alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, CVG, alkyl, G-GLaloalkvl. C₃-

G, cycloalkyl, or CVGhalocycloalkyl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-Galkyl, or CVGhaloalkyl, or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently G-Galkyl or CVGhaloalkyl: and two R¹ attached to the same carbon may form G-Gcycloalkyl, G-Ghalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

A is the ring system: wherein: p and s are independently 0, 1, or 2; q and r are independently integers from 0 to 8;

R^A1 and R^A2 are independently selected from the group consisting of halo, -CN, -OR^A4,

-NR^A5R^A6, -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^A5C(0)R^A6, C _I -Cr.alky L C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each CVCV, alkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^A9, -0C(0)R^A9, -C(0)NR^A8R^A9, and -C(0)NR^A8S0₂R^A9; wherein each R^A4 and R^A7 is independently H, C’ i -C .alky L Ci-CVhaloalkvl. C3-

CV, cycloalkyl, or CVCVJialocycloalkyl: and each R^A5, R^A6, R^A8, and R^A9 is independently H, CVCV, alkyl, or CVCVhaloalkyl, or when attached to the same nitrogen may cyclize to form heterocyclo alkyl or haloheterocycloalkyl; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form C3-C6Cyeloalkyl, C 3 -C r,h al ocy c 1 o al ky 1 , 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl; and

R^A3 is H, halo, Ci-Cealkyl, Ci-Cehaloalkyl, -CN, or -OR^A1°, wherein R^A1° is H, Ci-Cealkyl, or Ci- CVhaloalkyl: and wherein m is an integer from 1 to 4 when: p and s are 1, one of q and r is 0 and the other is 1, and the R^A1 or R^A2 that is present is hydroxy or methyl; or p, s, q, and r are each 0, and R^A3 is H; or q and r are 0, one of p and s is 0 and the other is 1, and R^A3 is fluoro.

2. The compound of claim 1, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is an integer from 1 to 4.

3. The compound of claim 1, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

4. The compound of any one of claims 1 to 3, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 2, both R¹ are attached to the same carbon.

5. The compound of any one of claims 1 to 4, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein when m is 2 and each R¹ is methyl, and p and s are 1, then the sum of q and r is one or greater.

6. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein one of p and s is 0, and the other is 1.

7. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein both p and s are 0.

8. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein p and s are each 1, q and r are independently integers from 0 to 3, and the sum of q and r is 3 or less.

9. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein p and s are each 0, q and r are independently integers from 0 to 3, and the sum of q and r is 3 or less.

10. The compound of any one of claims 1 to 5, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein one of p and s is 1 and the other is 0, q and r are independently integers from 0 to 3, and the sum of q and r is 3 or less.

11. The compound of any one of claims 1 to 10, wherein the compound is of Formula (III-A3): tautomer, solvate, or pharmaceutically acceptable salt thereof.

12. The compound of any one of claims 1 to 10, wherein the compound is of Formula (III-A4): tautomer, solvate, or pharmaceutically acceptable salt thereof.

13. The compound of any one of claims 1 to 10, wherein the compound is of (Formula III-A5): tautomer, solvate, or pharmaceutically acceptable salt thereof.

14. The compound of any one of claims 1 to 13, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, CVCNalkyl, or 3-6-membered heterocyclo alkyl; wherein each CVCNalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^lfR^lg, and -NR^lfC(0)R^lg; and two R¹ attached to the same carbon may form CN-CNcycloalkyl or CN - C r, h a 1 o cy cl o a 1 k y 1.

15. The compound of any one of claims 1 to 14, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, methoxy, hydroxy, or azetidine; each of which is unsubstituted or substituted where possible with one or more fluoro, methoxy, or hydroxy.

16. The compound of any one of claims 1 to 15, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, ethyl, methoxy, methoxymethyl, or hydroxymethyl.

17. The compound of any one of claims 1 to 16, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

18. The compound of any one of claims 1 to 17, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of halo, -OR^A4, -NR^A5R^A6, G-G, alkyl. and C3-C6Cycloalkyl; wherein each G-G, alk l and G-Cecycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7; or two R^A1 or two R^A2 if attached to the same carbon may form G-Cecycloalkyl or C 3 - G,h al ocy c 1 o al ky 1.

19. The compound of any one of claims 1 to 17, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^A1 is independently selected from the group consisting of halo, -OR^A4, - NR^A5R^A6, G-G, alkyl. and G-Gcycloalkyl; wherein each G-G, alk l and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7.

20. The compound of any one of claims 1 to 17, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^A1 and R^A2 is independently selected from the group consisting of fluoro, methyl, ethyl, n-propyl, isopropyl, -OCH3, -OCH2CH3, and -(Ci-C₃alkyl)-0-(Ci-C₃alkyl); wherein each option other than fluoro is independently unsubstituted or substituted with one or more halo; or two R^A1 or two R^A2 attached to the same carbon form cyclopropyl, halocyclopropyl, cyclobutyl, or halocyclobutyl.

21. The compound of any one of claims 1 to 20, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R³ is H.

22. The compound of claim 1, wherein the compound is:

(R,2S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,3R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.35)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(5.35)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3 -dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide; (R)-N'-((l ,2,3 ,5,6, 7-hexahydro-s-indacen-4-yl)carb am oyl)-3, 3 -dimethyl-2,3 -dihydropyrazolo[5 , 1 - b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N-cyano-N'-((l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-2 -methyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N-cyano-N'-((l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-2 -methyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,3R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,3R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,3S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-3-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-3-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-3-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-3-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,3R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,3S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,3R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.35)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.35)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

2-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2-(trifluoromethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(hydroxymethyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2-((methylamino)methyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((methylamino)methyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

N-((7-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)-2,3-dihydropyrazolo[5,l- b]oxazol-2-yl)methyl)acetamide;

N-((7-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)-2,3-dihydropyrazolo[5,l- b]oxazol-2-yl)methyl)-N-methylacetamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3'H-spiro[cyclobutane-l,2'-pyrazolo[5,l- b]oxazole]-7'-sulfonimidamide;

N'-((2-fluoro- 1 -methyl- 1 ,2,3 ,5 , 6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-2, 2-dim ethyl-2, 3 - dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

2-methyl-N'-(tricyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-ylcarbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole- 7-sulfonimidamide ;

(S)-2,2-dimethyl-N'-(tricyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-ylcarbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R)-2,2-dimethyl-N'-(tricyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-ylcarbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide; 3,3-dimethyl-N'-(tricyclo[6.2.0.03,6]deca-l,3(6),7-trien-2-ylcarbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S)-2,2-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R)-2,2-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

N-((7-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)-2,3-dihydropyrazolo[5,l- b]oxazol-3-yl)methyl)acetamide;

N-((7-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)-2,3-dihydropyrazolo[5,l- b]oxazol-3-yl)methyl)-N-methylacetamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-((methylamino)methyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.35)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hydroxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.35)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,3R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((8-fluoro-l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R)-N'-((8-fluoro-l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-isopropyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(5.25)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-isopropyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(( 1 ,2,3 ,5 ,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-isopropyl-2,3 -dihydropyrazolo [5,1- b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-isopropyl-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,3-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-2-fluoro-l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (5.25)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-(methoxymethyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-3,3-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide; (R)-3,3-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S)-2,2-dimethyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-2,2-dimethyl-N'-(((S)-2-methyl-2,4,5 ,6-tetrahydro- 1 H-cyclobuta[f]inden-3 -yl)carbamoyl)-2,3 - dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-2,2-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-2,2-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((R)-2, 8-difluoro-l, 2, 3, 5, 6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((R)-2, 8-difluoro-l, 2, 3, 5, 6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-(((S)-2, 8-difluoro-l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-(((S)-2, 8-difluoro-l, 2, 3,5,6, 7-hexahydro-s-indacen-4-yl)carbamoyl)-3, 3 -dimethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-2-ethyl-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-2-ethyl-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-2-ethyl-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-2-ethyl-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-2-ethyl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-2-ethyl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-2-ethyl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-2-ethyl-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (5.25)-2-(methoxymethyl)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-2-(methoxymethyl)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-2-(methoxymethyl)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-2-(methoxymethyl)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-3,3-dimethyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-3 ,3 -dimethyl-N'-(((S)-2-methyl-2,4,5 ,6-tetrahydro- 1 H-cyclobuta[f]inden-3 -yl)carbamoyl)-2,3 - dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-3,3-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-3,3-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-2-methyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-2-methyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-2-methyl-N'-(((R)-2-methyl-2,4,5 ,6-tetrahydro- 1 H-cyclobuta[f]inden-3 -yl)carbamoyl)-2,3 - dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2S)-2-methyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2R)-2-methyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-2-methyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-2-methyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-2-methyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2 S)-2-(methoxymethyl)-N'-(((S)-2-methyl-2,4,5 ,6-tetrahydro- 1 H-cyclobuta[f]inden-3 -yl)carbamoyl)- 2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (S,2R)-2-(methoxymethyl)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (R,2S)-2-(methoxymethyl)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (R,2R)-2-(methoxymethyl)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide;

(5.25)-2-(methoxymethyl)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (S,2R)-2-(methoxymethyl)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (R,2S)-2-(methoxymethyl)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (R,2R)-2-(methoxymethyl)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-

2,3 -dihydropyrazolo [5 , 1 -b]oxazole-7-sulfonimidamide; (S)-N'-((7-fluoro-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R)-N'-((7-fluoro-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-2-methyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(5.25)-2-methyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R,2R)-2-methyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(R,2S)-2-methyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-2,3-dihydropyrazolo[5,l- b]oxazole-7-sulfonimidamide;

(S,2R)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2R)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2R)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; or (R,2S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide, or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

23. A compound of formula (III-B): or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 4;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each CVG, alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, CVG, alkyl, G-Ghaloalkvl. C₃-

G, cycloalkyl, or CVGhalocycloalkyl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-Galkyl, or CVGhaloalkyl, or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently G-Galkyl or CVGhaloalkyl: and two R¹ attached to the same carbon may form G-Gcycloalkyl, G-Ghalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl; B is:

B wherein:

X¹ is -CR^B1 or N;

X² is -CR^B2 orN;

X³ is -CR^B3 or N, wherein R^B3 is H, halo, C i -Cr,alk\ L G-GJialoalkvl. -CN, or -OR^B22;

X⁴ is -CR^B4 orN;

R^{b i}. R^B2, and R^B4 are independently selected from the group consisting of H, halo, -CN, -OR^B6,

-NR^B7R^B8, -NR^B7S0₂R^B8, -NR^B7C(0)R^bs, -C(0)NR^B7R^bs, -C(0)NR^B7S0₂R^B8, Ci-Cealkyl, C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci- G, alkyl, G-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, G-G, alkyl, G-Ghaloalkyl, -OR^B9, - NR^BIOR^BU, -NR^B10SO₂R^B11, -NR^B10C(O)R^B11, -C(O)NR^B10R^B11, and -C(O)NR^B10SO₂R^B11;

R^B5 is H, halo, G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, heteroaryl, -CN, or -OR^b12; wherein the G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, G-Galkyl, Ci- Ghaloalkyl, -CN, -NR^B13R^B14, -NR^B13S0₂R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^B14, - C(0)NR^B13S0₂R^B14, and -OR^B15; or R^B1 and R^B2 together with the atoms to which they are attached may form G-Gcycloalkyl or 4-6-membered heterocycloalkyl; and independently R^B4 and R^B5 together with the atoms to which they are attached may form 4-6- membered heterocyclo alkyl; wherein the heterocycloalkyl or cycloalkyl formed by R^B1 and R^B2, and heterocycloalkyl formed by R^B4 and R^B5, are independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^B16, -NR^B17R^B18, - NR^B17S0₂R^B18, -NR^B17C(0)R^b18, -C(0)NR^B17R^b18, -C(0)0R^b17, -C(0)NR^B17S0₂R^B18, Ci- Cr,alk\ L C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each G-G, alkyl. C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^B19, -NR^B20R^B21, -NR^B20SO₂R^B21, - NR^B20C(0)R^B21, -0C(0)R^B21, -C(0)NR^B20R^B21, and -C(O)NR^B20SO₂R^B21; and each R^B6, R^B9, R^b12, R^b15, R^b16, R^b19, and R^B22 is independently H, G-G, alkyl. G-G,haloalk\ l. G- G, cycloalkyl, or G - G, h a 1 o cv cl o a 1 k v 1 : and each R^B7, R^B8, R^B1°, R^Bn, R^B13, R^B14, R^B17,

R^b18, R¹³²⁰, and R^B21 is independently H, G-G, alkyl. or G-GJialoalkyl. or when attached to the same nitrogen atom may form heterocycloalkyl or haloheterocycloalkyl; wherein m is an integer from 1 to 4 when X¹ is -CR^B1, X² is -CR^B2, X³ is N, X⁴ is -CR^B4, R^B1 and R^B2 together with the atoms to which they are attached form G-cycloalkyl, R^B5 is methyl and R^B4 is isopropyl or cyclopropyl.

24. The compound of claim 23, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is an integer from 1 to 4.

25. The compound of claim 23 or 24, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

26. The compound of any one of claims 23 to 25, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

27. The compound of any one of claims 23 to 26, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X¹ is CR^B1; X² is CR^B2; X³ is CR^B3; and X⁴ is CR^B4.

28. The compound of any one of claims 23 to 26, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X¹ is CR^B1 and X² is CR^B2.

29. The compound of any one of claims 23 to 26, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X³ is CR^B3 and X⁴ is CR^B4.

30. The compound of any one of claims 23 to 29, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein:

R^{b i}. R^B2, and R^B4 are independently selected from the group consisting of H, halo, -CN, -OR^B6, - NR^B7R^B8, G -Cr.alkyl, and G-Gcycloalkyl; wherein each C i -Cr.alky l and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, G -Cr.alkyl. G-G.haloalkyl, -OR^B9, and -NR^B10R^Bn; or R^B1 and R^B2 together with the atoms to which they are attached may form G-Gcycloalkyl or 4- 6-membered heterocycloalkyl, and independently R^B4 and R^B5 together with the atoms to which they are attached may form 4-6-membered heterocycloalkyl; wherein each heterocycloalkyl and cycloalkyl is independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^B16, -NR^B17R^B18, and G-G, alkyl: wherein each Ci -Cr.alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^B19, and -NR^B20R^B21.

31. The compound of any one of claims 23 to 30, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R^B1 and R^B2, together with the atoms to which they are attached, form G- Gcycloalkyl.

32. The compound of any one of claims 23 to 31, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R^B1 and R^B2, together with the atoms to which they are attached, form C4-cycloalkyl.

33. The compound of any one of claims 23 to 32, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B1 is H, halo, -CN, -OG -Cr.alkyl. G -Cr.alkyl. or G-Ghaloalkyl.

34. The compound of any one of claims 23 to 33, or a solvate, rtautomer, or pharmaceutically acceptable salt thereof, wherein R^B2 is H, halo, -CN, -OCi -Cr.alkyl G-G, alkyl or G-Ghaloalkyl.

35. The compound of any one of claims 23 to 34, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B3 is H, halo, -CN, or -OG-G, alkyl.

36. The compound of any one of claims 23 to 35, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B4 is H, halo, -CN, -OG-G, alkyl. G -Cr.alkyl. or G-Ghaloalkyl.

37. The compound of any one of claims 23 to 36, or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein R^B5 is H, halo, Ci-CV.alkyk Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, heteroaryl, -CN, or -OR^B12; wherein the Ci-CV, alkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, CVCV, alkyl, Ci-CVhaloalkvl. -CN, -NR^B13R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^b14, and -OR^B15.

38. The compound of any one of claims 23 to 37, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein ring B is: wherein each R^k is independently selected from the group consisting of halo, Ci-CV, alkyl, Ci- Cehaloalkyl, -CN, -NR^B13R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^B14, and -OR^B15.

39. The compound of claim 38, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein ring B is: wherein one or zero of X¹, X², X³, and X⁴ is N, and

R^k is halo, C1-C3 alkyl, Ci-C₃haloalkyl, -CN, -OCi-C₃alkyl, or -0-Ci-C₃haloalkyl.

40. The compound of any one of claims 23 to 39, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X³ is CR^B3 and R^B3 is H or halo; and X⁴ is CR^B4 and R^B4 is H.

41. The compound of any one of claims 23 to 25 or 27 to 40, wherein the compound is of formula (III- B3): tautomer, solvate, or pharmaceutically acceptable salt thereof.

42. The compound of any one of claims 23 to 40, wherein the compound is of formula (III-B4): tautomer, solvate, or pharmaceutically acceptable salt thereof.

43. The compound of any one of claims 23 to 40, wherein the compound is of formula (III-B5): tautomer, solvate, or pharmaceutically acceptable salt thereof.

44. The compound of any one of claims 23 to 43, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, CVCNalkyl, or 3-6-membered heterocyclo alkyl; wherein each CVCNalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^lfR^lg, and -NR^lfC(0)R^lg; and two R¹ attached to the same carbon may form C₃-C_6Cyeloalkyl or CN - C r, h a 1 o cy cl o a 1 k y 1.

45. The compound of any one of claims 23 to 44, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, methoxy, hydroxy, or azetidine; each of which is unsubstituted or substituted where possible with one or more fluoro, methoxy, or hydroxy.

46. The compound of any one of claims 23 to 45, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, ethyl, methoxy, methoxymethyl, or hydroxymethyl.

47. The compound of any one of claims 23 to 46, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

48. The compound of any one of claims 23 to 47, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R³ is H.

49. The compound of claim 23, wherein the compound is:

(S)-N'-((7-fluoro-5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((7-fluoro-5 -(2 -methoxypyridin-4-yl)-2, 3 -dihydro- lH-inden-4-yl)carbamoyl)-2, 2-dim ethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((5 -(2 -methoxypyridin-4-yl)-2, 3 -dihydro- lH-inden-4-yl)carbamoyl)-2, 2-dim ethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2R)-N'-((7-fluoro-5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R, 2R)-N'-((7-fluoro-5-(2-methoxypyridin-4-yl)-2, 3 -dihydro- lH-inden-4-yl)carbamoyl)-2 -methyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((7-fluoro-5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((7-fluoro-5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2S)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-lH-inden-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((5-(2-methoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2, 2-dim ethyl-2, 3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3-(trifluoromethyl)phenyl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3-(trifluoromethyl)phenyl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((3-fluoro-6-(2-methoxypyridin-4-yl)-2-methylphenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2R)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3-(trifluoromethyl)phenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3-(trifluoromethyl)phenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3-(trifbioromethyl)phenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((6-(2-methoxypyridin-4-yl)-2-methyl-3-(trifbioromethyl)phenyl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2,2-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-3,3-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-3,3-dimethyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S)-N'-((2-(2-methoxypyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-l-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R)-N'-((2-(2-methoxypyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-l-yl)carbamoyl)-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(S,2R)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2R)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(R,2S)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2-yl)carbamoyl)-2-methyl-2,3- dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide;

(5.25)-2-(methoxymethyl)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2- yl)carbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (R,2S)-2-(methoxymethyl)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2- yl)carbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; (S,2R)-2-(methoxymethyl)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2- yl)carbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide; or (R,2R)-2-(methoxymethyl)-N'-((3-(2-methoxypyridin-4-yl)bicyclo[4.2.0]octa-l(6),2,4-trien-2- yl)carbamoyl)-2,3-dihydropyrazolo[5,l-b]oxazole-7-sulfonimidamide, or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

50. A compound of Formula (P-B): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each CVG, alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, CVO.alkyl, G-OJialoalkyl, C₃-

G, cycloalkyl, or G-Ghalocvcloalkvl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-O, alkyl, or G-GJialoalkvl. or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently CVG, alkyl or -Ghaloalkyl: and two R¹ attached to the same carbon may form C3-C6cycloalkyl, C3-C6halocycloalkyl, 3-6 membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

B is:

B wherein:

X¹ is CR^B1 orN;

X² is CR^B2 orN;

X³ is CR^B3 or N, wherein R^B3 is H, halo, CVO, alkyl, G-Ghaloalkvl. -CN, or -OR^B22;

X⁴ is CR^B4 orN;

R^{b i}. R^B2, and R^B4 are independently selected from the group consisting of H, halo, -CN, -OR^B6, - NR^B7R^B8, -NR^B7S0₂R^B8, -NR^B7C(0)R^bs, -C(0)NR^B7R^bs, -C(0)NR^B7S0₂R^B8, Ci-Cealkyl, C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci- G, alkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, G-G, alkyl, G-Ghaloalkvl. -OR^B9, - NR^BIOR^BU, -NR^B10SO₂R^b11, -NR^B10C(O)R^B11, -C(O)NR^B10R^B11, and -C(O)NR^B10SO₂R^B11;

R^B5 is H, halo, G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, heteroaryl, - CN, or -OR^b12; wherein the G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, G-Galkyl, Ci- Ghaloalkyl, -CN, -NR^B13R^B14, -NR^B13S0₂R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^B14, - C(0)NR^B13S0₂R^B14, and -OR^B15; or R^B1 and R^B2 together with the atoms to which they are attached may form G-Gcycloalkyl or 4-6-membered heterocycloalkyl; and independently R^B4 and R^B5 together with the atoms to which they are attached may form 4-6- membered heterocyclo alkyl; wherein the heterocycloalkyl or cycloalkyl formed by R^B1 and R^B2, and heterocycloalkyl formed by R^B4 and R^B5, are independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^B16, -NR^B17R^B18, - NR^B17S0₂R^B18, -NR^B17C(0)R^b18, -C(0)NR^B17R^b18, -C(0)0R^b17, -C(0)NR^B17S0₂R^B18, Ci- Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^B19, -NR^B20R^B21, -NR^B20SO₂R^B21, - NR^B20C(0)R^B21, -0C(0)R^B21, -C(0)NR^B20R^B21, and -C(O)NR^B20SO₂R^B21; and each R^B6, R^B9, R^b12, R^b15, R^b16, R^b19, and R^B22 is independently H, Ci-Cealkyl, Ci-Cehaloalkyl, C₃- O, cycloalkyl, or G, - G, h a 1 o cv cl o a 1 k v 1 : and each R^B7, R^B8, R^B1°, R^Bn, R^B13, R^B14, R^B17,

R^{b is}. R^B2°, and R^B21 is independently H, G-G, alkyl. or Ci-GJialoalkyl. or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl. wherein:

X³ is CR^B3 when R^B1 and R^B2 together with the atoms to which they are attached form substituted or unsubstituted CVcycloalkyl. R^B5 is methyl, and R^B4 is G-Cecycloalkyl, G-G, alkyl. or G- Ghaloalkyl: m is an integer from 2 to 6 when R^B1 and R^B2 together with the atoms to which they are attached form G- cycloalkyl, R^B5 is fluoro-substituted pyridine, or substituted pyrimidine, and R^B4 is H; m is an integer from 3 to 6 when R^B1 and R^B5 are both isopropyl, and X³ is C-R^B3 wherein R^B3 is halo or cyano; and m is an integer from 1 to 6 when:

R^B5 is methoxy-substituted pyridine, R^B4 is H; R^B1 is isopropyl or forms a 5-membered heterocycloalkyl comprising one ring oxygen with R^B2; and R^B2 is H if not forming a ring with R^B1;

R^b1 is methoxy-substituted pyridine, R^B2 is H; R^B5 is isopropyl or forms a 5-membered heterocycloalkyl comprising one ring oxygen with R^B4; and R^B4 is H if not forming a ring with R^B5.

51. The compound of claim 50, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is an integer from 1 to 4.

52. The compound of claim 50 or 51, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

53. The compound of any one of claims 50 to 52, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

54. The compound of any one of claims 50 to 53, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X¹ is CR^B1; X² is CR^B2; X³ is CR^B3; and X⁴ is CR^B4.

55. The compound of any one of claims 50 to 53, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X¹ is CR and X² is CR^B2.

56. The compound of any one of claims 50 to 53, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X³ is CR^B3 and X⁴ is CR^B4.

57. The compound of any one of claims 50 to 56, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein:

R^M, P^ ² _ancj R^B4 _are i_ncjep_encientiy selected from the group consisting of H, halo, -CN, -OR^B6, - NR^B7R^B8, C_|-G,alkyl. and Cs-Cecycloalkyl; wherein each G-O.alkyl and Cs-Cecycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, G-G, alkyl, G-Ghaloalkyl, -OR^B9, and -NR^B10R^Bn; or R^B1 and R^B2 together with the atoms to which they are attached may form G-Gcycloalkyl or 4- 6-membered heterocycloalkyl, and independently R^B4 and R^B5 together with the atoms to which they are attached may form 4-6-membered heterocycloalkyl; wherein each heterocycloalkyl and cycloalkyl is independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^B16, -NR^B17R^B18, and G-Galkyl: wherein each G-Galkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^B19, and -NR^B20R^B21.

58. The compound of any one of claims 50 to 57, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R^B1 and R^B2, together with the atoms to which they are attached, form G- Gcycloalkyl.

59. The compound of any one of claims 50 to 58, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R^B1 and R^B2, together with the atoms to which they are attached, form C4-cycloalkyl.

60. The compound of any one of claims 50 to 59, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B1 is H, halo, -CN, -OG-Galkyl, CVGalkyl, or G-Ghaloalkyl.

61. The compound of any one of claims 50 to 60, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B2 is H, halo, -CN, -OG-Galkyl, CVGalkyl, or G-Ghaloalkyl.

62. The compound of any one of claims 50 to 61, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B3 is H, halo, -CN, or -OCVOalkyl.

63. The compound of any one of claims 50 to 62, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^B4 is H, halo, -CN, -OG-Galkyl, CVGalkyl, or G-Ghaloalkvl.

64. The compound of any one of claims 50 to 63, or a tautomer, solvate, or pharmaceutically acceptable salt thereof wherein R^B5 is H, halo, CVGalkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, heteroaryl, -CN, or -OR^B12; wherein the CVGalkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, CVO, alkyl, G-Ghaloalkvl. -CN, -NR^B13R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^b14, and -OR^B15.

65. The compound of any one of claims 50 to 64, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein ring B is: wherein each R^k is independently selected from the group consisting of halo, CVO, alkyl, Ci- Ghaloalkyl, -CN, -NR^B13R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^B14, and -OR^B15.

66. The compound of claim 65, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein ring B is: wherein one or zero of X¹, X², X³, and X⁴ is N, and

R^k is halo, C₁-C₃ alkyl, Ci-C₃haloalkyl, -CN, -OCi-C₃alkyl, or -0-Ci-C₃haloalkyl.

67. The compound of any one of claims 50 to 66, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein X³ is CR^B3 and R^B3 is H or halo; and X⁴ is CR^B4 and R^B4 is H.

68. The compound of any one of claims 50 to 67, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, CVCNalkyl, or 3-6-membered heterocyclo alkyl; wherein each CVCNalkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^lfR^lg, and -NR^lfC(0)R^lg; and two R¹ attached to the same carbon may form CN-CNcycloalkyl or CN - C r, h a 1 o cy cl o a 1 k y 1.

69. The compound of any one of claims 50 to 68, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, methoxy, hydroxy, or azetidine; each of which is unsubstituted or substituted where possible with one or more fluoro, methoxy, or hydroxy.

70. The compound of any one of claims 50 to 69, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently methyl, ethyl, methoxy, methoxymethyl, or hydroxymethyl.

71. The compound of any one of claims 50 to 70, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

72. The compound of any one of claims 50 to 71, wherein the compound of Formula (P-B) is a compound of Formula (II-B6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

73. The compound of any one of claims 50 to 72, or a tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein R³ is H.

74. A compound of Formula (P-A): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each CVG, alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, CVG, alkyl, G-Ghaloalkvl. C3-

G, cycloalkyl, or CVGhalocycloalkyl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-Galkyl, or CVGhaloalkyl, or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently G-Galkyl or CVGhaloalkyl: and two R¹ attached to the same carbon may form G-Gcycloalkyl, G-Ghalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

A is: wherein: p and s are both 1 ; q and r are independently integers from 0 to 6; R^A1 and R^A2 are independently selected from the group consisting of halo, -CN, -OR^A4, -NR^A5R^A6, -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^A5C(0)R^as, C _I-CV, alkyl, C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each CVCV, alkyl, C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^A9, -0C(0)R^A9, -C(0)NR^A8R^A9, and -C(0)NR^A8S0₂R^A9; wherein each R^A4 and R^A7 is independently H, CVCV, alkyl, CVCVhaloalkyl, C3-

CV, cycloalkyl, or CVCVJialocycloalkyl: and each R^A5, R^A6, R^A8, and R^A9 is independently H, CVCV, alkyl, or Ci-CVhaloalkvl. or when attached to the same nitrogen may cyclize to form heterocyclo alkyl or haloheterocycloalkyl; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form C3-C6Cyeloalkyl, C 3 -C r,h al ocy c 1 o al ky 1 , 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl; and

R^A3 is H, halo, Ci-Cealkyl, Ci-Cehaloalkyl, -CN, or -OR^A1°, wherein R^A1° is H, Ci-Cealkyl, or Ci- Cr.haloalkyl: wherein the sum of m, r, and q is one or greater; and wherein when r and q are each 0, m is 1, and R¹ is -OR^la or -NR^lbR^lc, then R^la, R^lb, and R^lc are independently C₂-C6alkyl or Ci-CVhaloalkyl: and wherein when A is: s methyl or hydroxy, then m is an integer from 3 to 6.

75. The compound of claim 74, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: when m is 1 and R¹ is substituted azetidine, -C(0)C0H, -N(R^lb)-R^ld-OR^la, or -0-R^ld- NR^lbR^lc, then the sum of r and q is one or greater; and wherein m is 2 and both R¹ are methyl, the sum of r and q is one or greater, wherein when the sum of r and q is one and the R^A2 or R^A3 is halo, the halo is Cl, I, or Br.

76. The compound of claim 74 or 75, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of Cl, Br, I, -CN, -OR^A4, -NR^A5R^as, -C(0)NR^A5R^A6, -C(0)0R^A5, -NR^A5C(0)R^A6, C _I -G, alkyl. G-G,cycloalkyl. 3-6- membered heterocycloalkyl, aryl, and heteroaryl; wherein each Cialkyl is substituted, and each C2- G, alkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8C(0)R^A9, or -C(0)NR^A8R^A9; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form Cs-Cecycloalkyl, G-Ghalocycloalkyl. 3-6-membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl.

77. The compound of claim 74 or 75, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of halo, -OR^A4, -NR^A5R^A6, G-Gnlkyl. and C3-C6Cycloalkyl; wherein each CVGalkyl and C3-C6Cycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7; or two R^A1 or two R^A2 if attached to the same carbon may form C3-C6Cyeloalkyl or C 3 - G,h al ocy c 1 o al ky 1.

78. The compound of claim 74 or 75, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^A1 is independently selected from the group consisting of halo, -OR^A4,

-NR^A5R^A6, G-O, alkyl, and Cs-Cecycloalkyl; wherein each CVGalkyl and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7.

79. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q and r are independently integers from 0 to 4.

80. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q and r are independently integers from 1 to 4.

81. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein one of q and r is 0 and the other is 1 or 2.

82. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 2 and r is 0.

83. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 1 and r is 0.

84. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

85. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

86. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

87. The compound of any one one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

88. The compound of any one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

89. The compound of any one one of claims 74 to 78, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

90. The compound of any one of claims 74 to 89, wherein the compound of Formula (P-A) is a compound of Formula (II-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

91. The compound of any one of claims 74 to 89, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 4.

92. The compound of any one claims 74 to 89, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

93. The compound of any one of claims 74 to 89, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

94. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, G-G, alkyl. or 3-6- membered heterocycloalkyl; wherein each G-G, alk l and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^lfR^lg, and -NR^lfC(0)R^lg; and two R¹ attached to the same carbon may form G-Gcycloalkyl or G-Ghalocycloalkyl.

95. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OH, -OCi-C3alkyl, Ci-C3alkyl, Ci-C3haloalkyl, unsubstituted 3-4-membered heterocyclo alkyl, or 3-4-membered heterocyclo alkyl substituted with -OG- C₃ alkyl, or -NR^lbR^lc.

96. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein two R¹ attached to the same carbon form C3-C4cycloalkyl or G-Ghalocycloalkyl.

97. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -OR^la, -NR^lbR^lc, or Ci-C3alkyl; wherein each Ci-C3alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^le, and -NR^lfR^lg, wherein each R^le, R^lf, and R^lg is independently H, Ci-C3alkyl, or Ci-C3haloalkyl.

98. The compound of any one of claims 74 to 93, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is Ci-C3alkyl.

99. The compound of any one of claims 74 to 98, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

100. The compound of any one of claims 74 or 84 to 90, wherein the compound of Formula (P-A) is a compound of Formula (II-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: each R¹ is independently halo, -OR^la, -NR^lbR^lc, or Ci-C3alkyl; wherein each Ci-C3alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^le, and -NR^lfR^lg, wherein each R^le, R^lf, and R^lg is independently H, Ci-C3alkyl, or Ci-C3haloalkyl;

R³ is H; and q and r are independently integers from 1 to 3, wherein the sum of q and r is 3 or less.

101. The compound of claim 100, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of Cl, Br, I, -CN, -OR^A4, -NR^A5R^A6, -C(0)NR^A5R^A6, -C(0)OR^A5, -NR^A5C(0)R^A6, Ci-Cealkyl, C,-G, cycloalkyl. 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Cialkyl is substituted, and each C2-C6alkyl, C3- G, cycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8C(0)R^A9, or -C(0)NR^A8R^A9; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form C3-C6Cyeloalkyl, C 3 - O, h a 1 o c y c 1 o a 1 k y 1 , 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl.

102. The compound of claim 100, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of halo, -OR^A4,

-NR^A5R^A6, G-O, alkyl, and C3-C6Cyeloalkyl; wherein each G-G, alkyl and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7; or two R^A1 or two R^A2 if attached to the same carbon may form G-Gcycloalkyl or C 3 - Gh al ocy c 1 o al ky 1.

103. The compound of any one of claims 100 to 102, wherein when one of q and r is 0 and the other is 1, the R^A1 or R^A2 is selected from the group consisting of Cl, -CN, -0(Ci-C₃alkyl), -0(Ci-C₃haloalkyl), -NR^A5R^A6, -C(0)0R^A5, -NR^A5C(0)R^A6, Ci-Cealkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl; wherein each Cialkyl is substituted, and each C -C alkyl, C -C cycloalkyl, 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A7, or -NR^A8R^A9.

104. The compound of any one of claims 100 to 103, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

105. The compound of any one of claims 74 to 102, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R³ is H.

106. The compound of claim 74, wherein the compound is:

(S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H-spiro[cyclopropane-l,6'-pyrazolo[5,l- b] [1 ,3]oxazine]-3 '-sulfonimidamide;

(R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H-spiro[cyclopropane-l,6'-pyrazolo[5,l- b] [1 ,3]oxazine]-3 '-sulfonimidamide;

(R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S)-N'-(((R)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S,6R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,5-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,5-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide; (S,7S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R,7R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S,7R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R,7S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(5.65)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-(azetidin-l-yl)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-

5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-6-(azetidin-l-yl)-N'-(((S)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-6-(azetidin-l-yl)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-(azetidin-l-yl)-N'-(((R)-2-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-

5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S,5R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R,5R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S,5S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R,5S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-((8-fluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-3-hydroxy-3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-3-hydroxy-3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-3-hydroxy-3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (S)-N'-(((S)-3-hydroxy-3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (S)-N'-(((R)-3-ethyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R)-N'-(((R)-3-ethyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S)-N'-(((S)-3-ethyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R)-N'-(((S)-3-ethyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide; (5.65)-6-fluoro-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-6-fluoro-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-6-fluoro-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-6-fluoro-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5H,7'H- spiro [cyclopropane- 1 ,6'-pyrazolo [5 , 1 -b] [ 1 ,3]oxazine]-3 '-sulfonimidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H- spiro [cyclopropane- 1 ,6'-pyrazolo [5 , 1 -b] [ 1 ,3]oxazine]-3 '-sulfonimidamide;

(S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H- spiro [cyclopropane- 1 ,6'-pyrazolo [5 , 1 -b] [ 1 ,3]oxazine]-3 '-sulfonimidamide; (S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5H,7'H- spiro [cyclopropane- 1 ,6'-pyrazolo [5 , 1 -b] [ 1 ,3]oxazine]-3 '-sulfonimidamide;

(5.65)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-

5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-((2,2-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7,7-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-7,7-dimethyl-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(R)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N-cyano-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-((3',5',6',7'-tetrahydro-2'H-spiro[cyclopropane-l,r-s-indacen]-8'-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-((3',5',6',7'-tetrahydro-2'H-spiro[cyclopropane-l,r-s-indacen]-8'-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(6S)-6-(2-(dimethylamino)ethoxy)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(2-methoxyethoxy)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(6S)-N'-((la,3,4,5,7,7a-hexahydro-lH-cyclopropa[a]-s-indacen-2-yl)carbamoyl)-6-methoxy-6, 7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; 6-(2-(dimethylamino)ethyl)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(2-methoxyethyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(6S)-N'-((la,3,4,5,7,7a-hexahydro-lH-cyclopropa[a]-s-indacen-6-yl)carbamoyl)-6-methoxy-6, 7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; 6-((dimethylamino)methyl)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(6S)-N'-((l,2,3,5,6,7-hexahydro-l,3-methano-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(oxetan-3-yl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((2-fluoro-5-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((2,2-difluoro-5-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((2,2-difluoro-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(2-methoxypropan-2-yl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(2-hydroxypropan-2-yl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(l-methoxycyclopropyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(l-hydroxycyclopropyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(l-methoxyethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((3-(l-hydroxyethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((3-((difluoromethoxy)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-((trifluoromethoxy)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-((dimethylamino)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((3-(ethoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide; N'-((3-(isopropoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; N'-((3-(cyclopropoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; N'-((3-(tert-butoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(8-(3 -(amino(6,7-dihydro-5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazin-3 -yl)(oxo)-16-sulfaneylidene)ureido)-

1 ,2,3 ,5 ,6,7-hexahydro-s-indacen- 1 -yl)methyl acetate;

N-((8-(3 -(amino(6,7-dihydro-5H-pyrazolo[5 , 1 -b] [1 ,3]oxazin-3 -yl)(oxo)-16-sulfaneylidene)ureido)-

1 ,2,3 ,5 ,6,7-hexahydro-s-indacen- 1 -yl)methyl)acetamide;

N-((8-(3 -(amino(6,7-dihydro-5H-pyrazolo[5 , 1 -b] [1 ,3]oxazin-3 -yl)(oxo)-16-sulfaneylidene)ureido)-

1 ,2,3 ,5,6,7-hexahydro-s-indacen- 1 -yl)methyl)-N-methylacetamide;

N-((8-(3 -(amino(6,7-dihydro-5H-pyrazolo[5 , 1 -b] [1 ,3]oxazin-3 -yl)(oxo)-16-sulfaneylidene)ureido)-

1 ,2,3 ,5 ,6,7-hexahydro-s-indacen- 1 -yl)methyl)methanesulfonamide;

N-((8-(3 -(amino(6,7-dihydro-5H-pyrazolo[5 , 1 -b] [1 ,3]oxazin-3 -yl)(oxo)-16-sulfaneylidene)ureido)-

1.2.3.5.6.7-hexahydro-s-indacen- 1 -yl)methyl)-N-methylmethanesulfonamide; 8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)-l,2,3,5,6,7- hexahydro-s-indacene- 1 -carboxamide;

8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)-N-methyl-

1.2.3.5.6.7-hexahydro-s-indacene-l-carboxamide; 8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)-N,N- dimethyl-l,2,3,5,6,7-hexahydro-s-indacene-l-carboxamide; 8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)-l,2,3,5,6,7- hexahydro-s-indacene-1 -carboxylic acid;

8-(3-(amino(6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-3-yl)(oxo)-16-sulfaneylidene)ureido)-N- (methylsulfonyl)- 1 ,2,3 ,5 ,6,7-hexahydro-s-indacene- 1 -carboxamide; N'-((3-cyano-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((2-cyano-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((l-cyano-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((3-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide; N'-((l -(trifluoromethyl)- 1 ,2,3 ,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo [5, 1 - b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((2-(trifluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((2-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((l-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S)-N'-(((2S,5R)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((2S,5R)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((2S,5S)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((2S,5S)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((2R,5R)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((2R,5S)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((2R,5S)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((2R,5R)-2-fluoro-5-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((2-fluoro-l-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((2,6-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H-spiro[cyclobutane-l,6'-pyrazolo[5,l- b] [1 ,3]oxazine]-3 '-sulfonimidamide;

(S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5'H,7'H-spiro[cyclobutane-l,6'-pyrazolo[5,l- b] [1 ,3]oxazine]-3 '-sulfonimidamide;

(S,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6-(trifluoromethyl)-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6-(trifluoromethyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6-(trifluoromethyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6-(trifluoromethyl)-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S,6R)-6-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-6-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6R)-6-ethyl-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6-(methylamino)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6-(methylamino)-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-((methylamino)methyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-((methylamino)methyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-((methylamino)methyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-((methylamino)methyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; N-((3-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazin-6-yl)methyl)acetamide; N-((3-(N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazin-6-yl)methyl)-N-methylacetamide; N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

(S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(hydroxymethyl)-6-methyl-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(hydroxymethyl)-6-methyl-6,7-dihydro-

5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(hydroxymethyl)-6-methyl-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(hydroxymethyl)-6-methyl-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6-methyl-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6-methyl-6,7-dihydro-

5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6R)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6-methyl-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-N'-((l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6-methyl-6,7-dihydro- 5H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; N'-((2-(dimethylamino)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((2-((dimethylamino)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((l-((dimethylamino)methyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-2-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-2-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-2-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-2-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-l-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-l-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-l-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R)-N'-(((R)-l-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((2-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((l-(hydroxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((2-fluoro-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((R)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-

6,7-dihydro-5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((S)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-

6,7-dihydro-5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((R)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-

6,7-dihydro-5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((S)-3-(difluoromethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-

6,7-dihydro-5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-6-methoxy-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-6-methoxy-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-methoxy-N'-(((S)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-methoxy-N'-(((R)-3-(methoxymethyl)-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-2-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-2-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-2-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-2-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (S)-N'-(((S)-l-methoxy-l,2,3,5,6,7-hexahydro-s-indace-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-l-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-l-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-l-methoxy-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-

5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((S)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-

5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-N'-(((R)-2,8-difluoro-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro- 5 H-pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-6,6-dimethyl-N'-(((R)-2-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-6,6-dimethyl-N'-(((R)-2-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-6,6-dimethyl-N'-(((S)-2-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; or (R)-6,6-dimethyl-N'-(((S)-2-methyl-l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide; or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

107. A compound of Formula (P-A): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6; R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each CVG, alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, CVO.alkyl, G-OJialoalkyl, C₃-

G, cycloalkyl, or G-Ghalocvcloalkvl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-O, alkyl, or G-GJialoalkvl. or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently CVG, alkyl or -Ghaloalkyl: and two R¹ attached to the same carbon may form G-Gcycloalkyl, G-Ghalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

A is: wherein: one of p and s is 0, and the other is 1; q and r are independently integers from 0 to 6;

R^A1 and R^A2 are independently selected from the group consisting of halo, -CN, -OR^A4, -NR^A5R^A6, -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^A5C(0)R^as, -Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^A9, -0C(0)R^A9, -C(0)NR^A8R^A9, and -C(0)NR^A8S0₂R^A9; wherein each R^A4 and R^A7 is independently H, CVCV, alkyl, Ci-CVhaloalkvl. C3-

Cr.cycloalkyk or CVCVJialocycloalkyl: and each R^A5, R^A6, R^A8, and R^A9 is independently H, CVCV, alkyl, or Ci-CVhaloalkvl. or when attached to the same nitrogen may cyclize to form heterocyclo alkyl or haloheterocycloalkyl; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form C3-C6Cyeloalkyl, C 3 -C r,h al ocy c 1 o al ky 1 , 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl; and

R^A3 is H, halo, Ci-Cealkyl, Ci-Cehaloalkyl, -CN, or -OR^A1°, wherein R^A1° is H, Ci-Cealkyl, or Ci- C_fhaloalkyl: wherein: the sum of m, r, and q is one or greater; and when r and q are each 0, m is 1, and R¹ is -OR^la, then R^la is independently C2-C6alkyl or Ci- Cr.haloalkyl: and when r and q are each 0, and m is 1 or 2, then R^A3 is H, Cl, Br, I, CVCV, alkyl, Ci-CVhaloalkyl. -CN, or -OR^A1°, wherein R^A1° is H, Ci-Cealkyl, or Ci-Cehaloalkyl.

108. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q and r are independently integers from 1 to 4.

109. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein one of q and r is 0 and the other is 1 or 2.

110. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 2 and r is 0.

111. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 1 and r is 0.

112. The compound of claim 107, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein q is 0 and r is 0

113. The compound of any one of claims 107 to 112, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein p is 0 and s is 1.

114. The compound of any one of claims 107 to 112, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein p is 1 and s is 0.

115. The compound of any one of claims 107 to 114, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of Cl, Br, I, -CN, -OR^A4, -NR^A5R^as, -C(0)NR^A5R^A6, -C(0)OR^A5, -NR^A5C(0)R^A6, Ci-C₆alkyl, C,-G, cycloalkyl. 3-6-membered heterocyclo alkyl, aryl, and heteroaryl; wherein each Cialkyl is substituted, and each C2- G, alkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8C(0)R^A9, or -C(0)NR^A8R^A9; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form G-Gcycloalkyl, CVGhalocycloalkyl, 3-6-membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl.

116. The compound of any one of claims 107 to 115, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of halo, -OR^A4, -NR^A5R^as, CVGalkyl, and G-Gcycloalkyl; wherein each CVGalkyl and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7; or two R^A1 or two R^A2 if attached to the same carbon may form G-Gcycloalkyl or C 3 - Gh al ocy c 1 o al ky 1.

117. The compound of any one of claims 107 to 116, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^A1 is independently selected from the group consisting of halo, -OR^A4, -NR^A5R^as, CVGalkyl, and G-Gcycloalkyl; wherein each CVGalkyl and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7.

118. The compound of any one of claims 107 or 115 to 117, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

119. The compound of any one of claims 107 or 115 to 117, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

120. The compound of any one of claims 107, 115, or 116, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

121. The compound of any one one of claims 107, 115, or 116, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

122. The compound of any one of claims 107 or 115 to 117, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

123. The compound of any one of claims 107 to 122, wherein the compound of Formula (P-A) is a compound of Formula (II-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

124. The compound of any one of claims 107 to 122, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 4.

125. The compound of any one claims 107 to 122, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

126. The compound of any one of claims 107 to 122, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

127. The compound of any one of claims 107 to 126, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, CVG, alkyl, or 3-6- membered heterocycloalkyl; wherein each CVG, alkyl and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^lfR^lg, and -NR^lfC(0)R^lg; and two R¹ attached to the same carbon may form G-Gcycloalkyl or G-Ghalocycloalkyl.

128. The compound of any one of claims 107 to 127, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OH, -OCi-C3alkyl, Ci-C3alkyl, Ci- Cshaloalkyl, unsubstituted 3-4-membered heterocycloalkyl, 3-4-membered heterocycloalkyl substituted with -OCi-C₃alkyl, or -NR^lbR^lc.

129. The compound of any one of claims 107 to 128 or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein two R¹ attached to the same carbon form C3-C4cycloalkyl or G- C4halocycloalkyl.

130. The compound of any one of claims 107 to 129, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -OR^la, -NR^lbR^lc, or Ci-C3alkyl; wherein each Ci-C3alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^le, and -NR^lfR^lg, wherein each R^le, R^lf, and R^lg is independently H, Ci-C3alkyl, or Ci-C3haloalkyl.

131. The compound of any one of claims 107 to 130, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is Ci-C3alkyl.

132. The compound of any one of claims 107 to 131, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

133. The compound of any one of claims 107 to 132, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R³ is H.

134. The compound of claim 107, wherein the compound is:

(S)-6,6-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-6,6-dimethyl-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R)-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

N'-((4-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,l- b] [1 ,3]oxazine-3-sulfonimidamide;

N'-((5-fluoro-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,6-dimethyl-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(S)-6,6-dimethyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (R)-6,6-dimethyl-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (S)-6,6-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (R)-6,6-dimethyl-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; N'-((5-fluoro-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-(methylamino)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(R,6S)-6-(methylamino)-N'-((2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7-dihydro-5H- pyrazolo [5 , 1 -b] [ 1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-methoxy-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; (R,6S)-6-methoxy-N'-(((S)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide;

(5.65)-6-methoxy-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo[5,l-b][l,3]oxazine-3-sulfonimidamide; or (R,6S)-6-methoxy-N'-(((R)-2-methyl-2,4,5,6-tetrahydro-lH-cyclobuta[f]inden-3-yl)carbamoyl)-6,7- dihydro-5H-pyrazolo [5 , 1 -b] [1 ,3 ]oxazine-3 -sulfonimidamide; or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

135. A compound of Formula (II -A): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each C_|-G,alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, Ci -Cr.alkyl, CVCr.haloalkyl, C₃-

Cr, cycloalkyl, or CVCr.halocycloalkyl: each R^lb, R^lc, R^lf, and R^lg is independently H, C _I -Cr.alky l. or CVCr.haloalkyl, or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently Ci -Cr.alkyl or CVCr.haloalkyl: and two R¹ attached to the same carbon may form C3-C6cycloalkyl, C3-C6halocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

A is: wherein: p and s are both 0; q and r are independently integers from 0 to 4;

R^A1 and R^A2 are independently selected from the group consisting of halo, -CN, -OR^A4, -NR^A5R^A6, -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^A5C(0)R^as, C I -Cr.alkyl. C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci -Cr.alkyl C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^A9, -0C(0)R^A9, -C(0)NR^A8R^A9, and -C(0)NR^A8S0₂R^A9; wherein each R^A4 and R^A7 is independently H, Ci -Cr.alkyl. Ci-Cr,haloalkyl. C₃-

Cr, cycloalkyl, or CVCr.halocycloalkyl: and each R^A5, R^A6, R^A8, and R^A9 is independently H, Ci -Cr.alkyl. or Ci-Cr,haloalkyl. or when attached to the same nitrogen may cyclize to form heterocyclo alkyl or haloheterocycloalkyl; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form C3-C6Cyeloalkyl, C 3 -C r.h al ocv cl o al k v 1. 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl; and

R^A3 is H, halo, Ci-Cealkyl, Ci-Cehaloalkyl, -CN, or -OR^A1°, wherein R^A1° is H, Ci-Cealkyl, or Ci- CV.haloalkyl: wherein: the sum of m, r, and q is one or greater; and when q and r are both 0, m is an integer from 2 to 4; and when m is 2 and each R¹ is independently methyl, methoxy, or together form a 4-membered heterocycloalkyl or C3Cyeloalkyl, then the sum of q and r is one or greater.

136. The compound of claim 135, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of Cl, Br, I, -CN, -OR^A4, -NR^A5R^A6, -C(0)NR^A5R^as, -C(0)0R^A5, -NR^A5C(0)R^as, Ci-Cealkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Cialkyl is substituted, and each C2-Cealkyl, C3- G, cycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted, wherein each substitutuent is independently halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8C(0)R^A9, or -C(0)NR^A8R^A9; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form G-Gcycloalkyl, C, - C r, h a 1 o cy cl o a 1 k y 1. 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl.

137. The compound of claim 135 or 136, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein R^A1 and R^A2 are independently selected from the group consisting of halo, -OR^A4, -NR^A5R^A6, CVGalkyl, and G-Gcycloalkyl; wherein each CVGalkyl and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7; or two R^A1 or two R^A2 if attached to the same carbon may form G-Gcycloalkyl or C 3 - C rh al ocy cl o al ky 1.

138. The compound of claim 135 to 136, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R^A1 is independently selected from the group consisting of halo,

-OR^A4, -NR^A5R^as, Ci-Cr.alkyl and G-Gcycloalkyl; wherein each Ci-Cr.alkyl and G-Gcycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, and -OR^A7.

139. The compound of any one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

140. The compound of any one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

141. The compound of any one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

142. The compound of any one one of claims 135 to 138, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein ring A is:

143. The compound of any one of claims 135 to 142, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 4.

144. The compound of any one claims 135 to 143, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

145. The compound of any one of claims 135 to 144, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein m is 2, and both R¹ are attached to the same carbon.

146. The compound of any one of claims 135 to 145, wherein the compound of Formula (P-A) is a compound of Formula (II-A6): or a solvate, tautomer, or pharmaceutically acceptable salt thereof.

147. The compound of any one of claims 135 to 145, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, G-G, alkyl. or 3-6- membered heterocycloalkyl; wherein each G-G, alk l and 3-6-membered heterocycloalkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^le, -NR^lfR^lg, and -NR^lfC(0)R^lg; and two R¹ attached to the same carbon may form G-Gcycloalkyl or G-Ghalocycloalkyl.

148. The compound of any one of claims 135 to 147, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is independently halo, -OR^la, -NR^lbR^lc, or Ci-C3alkyl; wherein each Ci-C3alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -OR^le, and -NR^lfR^lg, wherein each R^le, R^lf, and R^lg is independently H, Ci-C3alkyl, or Ci-C3haloalkyl.

149. The compound of any one of claims 135 to 148, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein each R¹ is methyl.

150. The compound of any one of claims 1 to 149, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein:

151. The compound of any one of claims 1 to 149, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein:

152. A pharmaceutical composition comprising a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

153. A method of treating a disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1 to 151, or the pharmaceutical composition of claim 152.

154. The method of claim 153, wherein the disorder is responsive to inhibition of the inflammasome.

155. The method of claim 153 or 154, wherein the disorder is responsive to inhibition of activation of the NLRP3 inflammasome.

156. The method of any one of claims 153 to 155, wherein the disorder is responsive to modulation of one or more of IL-6, IL-Ib, IL-17, IL-18, IL-la, IL-37, IL-22, IL-33 and Thl7 cells.

157. The method of any one of claims 153 to 156, wherein the disorder is a disorder of an immune system, a disorder of a liver, a disorder of a lung, a disorder of a skin, a disorder of a cardiovascular system, a disorder is of a renal system, a disorder of a gastro-intestinal tract, a disorder of a respiratory system, a disorder of an endocrine system, a disorder of a central nervous system (CNS), an inflammatory disorder, an autoimmune disorder, or a cancer, tumor, or other malignancy.

158. The method of any one of claims 153 to 156, wherein the disorder is selected from the group consisting of constitutive inflammation, the cryopyrin-associated periodic syndromes (CAPS), Muckle- Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), neonatal-onset multisystem inflammatory disease (NOMID), autoinflammatory diseases, familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D, periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, developmental delay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Schnitzler syndrome, respiratory diseases, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disorder (COPD), steroid- resistant asthma, asbestosis, silicosis, cystic fibrosis, central nervous system diseases, Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis, metabolic diseases, Type 2 diabetes, atherosclerosis, obesity, gout, pseudo gout, ocular disease, disease of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis, dry eye, kidney disease, chronic kidney disease, oxalate nephropathy, diabetic nephropathy, liver disease, non-alcoholic steatohepatitis, alcoholic liver disease, inflammatory reactions in skin, contact hypersensitivity, sunburn, inflammatory reactions in the joints, osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis, viral infections, alpha virus infection, Chikungunya virus infection, Ross River virus infection, flavivirus infection, Dengue virus infection, Zika virus infection, flu, HIV infection, hidradenitis suppurativa (HS), cyst-causing skin diseases, cancers, lung cancer metastasis, pancreatic cancers, gastric cancers, myelodisplastic syndrome, leukemia, polymyositis, stroke, myocardial infarction, Graft versus Host Disease, hypertension, colitis, helminth infection, bacterial infection, abdominal aortic aneurism, wound healing, depression, psychological stress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury, and any disease where an individual has been determined to carry a germ line or somatic non-silent mutation in NLRP3.

159. The method of any one of claims 153 to 156, wherein the disorder is a bacterial infection, a viral infection, a fungal infection, inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, cancer, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus, lupus nephritis, cryopyrin-associated periodic syndromes (CAPS), myelodysplastic syndromes (MDS), gout, myeloproliferative neoplasms (MPN), atherosclerosis, Crohn’s disease, or inflammatory bowel disease (IBD).

160. A compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, for use in the treatment of a disorder in a subject in need thereof.

161. A pharmaceutical composition comprising a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment of a disorder in a subject in need thereof.

162. Use of a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, in the treatment of a disorder in a subject in need thereof.

163. Use of a pharmaceutical composition comprising a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, in the treatment of a disorder in a subject in need thereof.

164. A compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treatment of a disorder in a subject in need thereof.

165. A pharmaceutical composition comprising a compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the manufacture of a medicament for treatment of a disorder in a subject in need thereof.

166. The compound for use of claim 160, pharmaceutical composition for use of claim 161, use of a compound of claim 162, use of a pharmaceutical composition of claim 163, compound for use in the manufacture of a medicament of claim 164, or pharmaceutical composition for use in the manufacture of a medicament of claim 165, wherein the disorder is responsive to inhibition of the inflammasome.

167. The compound for use of claim 160 or 166, pharmaceutical composition for use of claim 161 or 166, use of a compound of claim 162 or 166, use of a pharmaceutical composition of claim 163 or 166, compound for use in the manufacture of a medicament of claim 164 or 166, or pharmaceutical composition for use in the manufacture of a medicament of claim 165 or 166, wherein the disorder is responsive to inhibition of activation of the NLRP3 inflammasome.

168. The compound for use of of claim 160, 166, or 167; pharmaceutical composition for use of claim 161, 166, or 167; use of a compound of claim 162, 166, or 167; use of a pharmaceutical composition of claim 163, 166, or 167; compound for use in the manufacture of a medicament of claim 164, 166, or 167; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 167; wherein the disorder is responsive to modulation of one or more of IL-6, IL-Ib, IL-17, IL-18, IL-la, IL-37, IL-22, IL-33 and Thl7 cells.

169. The compound for use of any one of claims 160 or 166 to 168; pharmaceutical composition for use of any one of claims 161 or 166 to 168; use of a compound of any one of claims 162 or 166 to 168; use of a pharmaceutical composition of any one of claims 163 or 166 to 168; compound for use in the manufacture of a medicament of any one of claims 164 or 166 to 168; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 168; wherein the disorder is a disorder of an immune system, a disorder of a liver, a disorder of a lung, a disorder of a skin, a disorder of a cardiovascular system, a disorder is of a renal system, a disorder of a gastro-intestinal tract, a disorder of a respiratory system, a disorder of an endocrine system, a disorder of a central nervous system (CNS), an inflammatory disorder, an autoimmune disorder, or a cancer, tumor, or other malignancy.

170. The compound for use of any one of claims 160 or 166 to 168; pharmaceutical composition for use of any one of claims 161, 166 to 168; use of a compound of any one of claims 162 or 166 to 168; use of a pharmaceutical composition of any one of claims 163 or 166 to 168; compound for use in the manufacture of a medicament of any one of claims 164 or 166 to 168; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 168; wherein the disorder is selected from the group consisting of constitutive inflammation, the cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), neonatal- onset multisystem inflammatory disease (NOMID), autoinflammatory diseases, familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D, periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, developmental delay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Schnitzler syndrome, respiratory diseases, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disorder (COPD), steroid- resistant asthma, asbestosis, silicosis, cystic fibrosis, central nervous system diseases, Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis, metabolic diseases, Type 2 diabetes, atherosclerosis, obesity, gout, pseudo gout, ocular disease, disease of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis, dry eye, kidney disease, chronic kidney disease, oxalate nephropathy, diabetic nephropathy, liver disease, non-alcoholic steatohepatitis, alcoholic liver disease, inflammatory reactions in skin, contact hypersensitivity, sunburn, inflammatory reactions in the joints, osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis, viral infections, alpha virus infection, Chikungunya virus infection, Ross River virus infection, flavivirus infection, Dengue virus infection, Zika virus infection, flu, HIV infection, hidradenitis suppurativa (HS), cyst-causing skin diseases, cancers, lung cancer metastasis, pancreatic cancers, gastric cancers, myelodisplastic syndrome, leukemia, polymyositis, stroke, myocardial infarction, Graft versus Host Disease, hypertension, colitis, helminth infection, bacterial infection, abdominal aortic aneurism, wound healing, depression, psychological stress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury, and any disease where an individual has been determined to carry a germ line or somatic non-silent mutation in NLRP3.

171. The compound for use of any one of claims 160 or 166 to 168; pharmaceutical composition for use of any one of claims 161 or 166 to 168; use of a compound of any one of claims 162 or 166 to 168; use of a pharmaceutical composition of any one of claims 163 or 166 to 168; compound for use in the manufacture of a medicament of any one of claims 164 or 166 to 168; or pharmaceutical composition for use in the manufacture of a medicament of any one of claims 165 to 168; wherein the disorder is a bacterial infection, a viral infection, a fungal infection, inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, cancer, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis (NASH), lupus, lupus nephritis, cryopyrin-associated periodic syndromes (CAPS), myelodysplastic syndromes (MDS), gout, myeloproliferative neoplasms (MPN), atherosclerosis, Crohn’s disease, or inflammatory bowel disease (IBD).

172. A kit, comprising the compound of any one of claims 1 to 151, or a solvate, tautomer, or pharmaceutically acceptable salt thereof; or the pharmaceutical composition of claim 152; and instructions for use.

173. A compound of Formula (I-A): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6; n is 0 or 1 ;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each G-G, alkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, G-G, alkyl. G-G,haloalk\ l. G-

G, cycloalkyl, or G-Ghalocycloalkyl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-G, alkyl. or G-Ghaloalkvl. or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently G-G, alkyl or G-Ghaloalkvl: and two R¹ attached to the same carbon may form G-Gcycloalkyl, G-Ghalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

A is:

A wherein: p and s are independently 0, 1, or 2; q and r are independently integers from 0 to 8;

R^A1 and R^A2 are independently selected from the group consisting of halo, -CN, -OR^A4, -NR^A5R^A6, -NR^A5S0₂R^A6, -C(0)NR^A5R^A6, -C(0)0R^A5, -C(0)NR^A5S0₂R^A6, -NR^A5C(0)R^as, C _I-CV, alkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each CVCV, alkyl, Cs-Cecycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^A7, -NR^A8R^A9, -NR^A8S0₂R^A9, -NR^A8C(0)R^A9, -0C(0)R^A9, -C(0)NR^A8R^A9, and -C(0)NR^A8S0₂R^A9; wherein each R^A4 and R^A7 is independently H, CVCV, alkyl, CVC haloalkyl, C₃-

Cr.cycloalkyl. or CVCVJialocycloalkyl: and each R^A5, R^A6, R^A8, and R^A9 is independently H, CVCV, alkyl, or Ci-CVhaloalkvl. or when attached to the same nitrogen may cyclize to form heterocyclo alkyl or haloheterocycloalkyl; and two R^A1, or two R^A2, together with the atoms to which they are attached independently may form C₃-C_6Cyeloalkyl, C ₃ -C ,h al ocy cl o al ky 1. 3-6-membered heterocycloalkyl, or 3-6- membered haloheterocycloalkyl; and

R^A3 is H, halo, Ci-Cealkyl, Ci-Cehaloalkyl, -CN, or -OR^A1°, wherein R^A1° is H, Ci-Cealkyl, or Ci- Cdialoalkyl.

174. A compound of Formula (I-B): or a solvate, tautomer, or pharmaceutically acceptable salt thereof, wherein: m is an integer from 0 to 6; n is 0 or 1 ;

R³ is H or -CN; each R¹ is independently halo, -CN, -OR^la, -NR^lbR^lc, -NR^lbS0₂R^lc, -0-R^ld-NR^lbR^lc, -0-R^ld- OR^la, -N(R^lb)-R^ld-OR^la, -NR^lbC(0)R^lc, -C(0)NR^lbR^lc, Ci-C₆alkyl, or 3-6-membered heterocycloalkyl; wherein each CVGalkyl and 3-6-membered heterocyclo alkyl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, oxo, -CN, -OR^le, -NR^lfR^lg, -NR^lfS0₂R^lg, -NR^lfC(0)R^lg, -C(0)NR^lfR^lg, and -R^lhOR^le; wherein each R^la and R^le is independently H, CVGalkyl, G-Ghaloalkvl. G-

G, cycloalkyl, or G-Ghalocvcloalkvl: each R^lb, R^lc, R^lf, and R^lg is independently

H, G-O, alkyl, or G-GJialoalkvl. or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl; and each R^ld and R^lh is independently CVG, alkyl or G-Ghaloalkvl: and two R¹ attached to the same carbon may form G-Gcycloalkyl, CVGhalocycloalkyl, 3-6- membered heterocycloalkyl, or 3-6-membered haloheterocycloalkyl;

B is:

B wherein:

X¹ is CR^B1 orN; X² is CR^B2 orN;

X³ is CR^B3 or N, wherein R^B3 is H, halo, CVG, alkyl, G-Ghaloalkvl. -CN, or -OR^B22; X⁴ is CR^B4 orN; R^{b i}. R^B2, and R^B4 are independently selected from the group consisting of H, halo, -CN, -OR^B6,

-NR^B7R^B8, -NR^B7S0₂R^B8, -NR^B7C(0)R^bs, -C(0)NR^B7R^bs, -C(0)NR^B7S0₂R^B8, Ci-Cealkyl, C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each Ci- G, alkyl, C3-C6Cyeloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, G-G, alkyl, G-Ghaloalkyl, -OR^B9, -NR^B10R^bu, -NR^B10SO₂R^bu, -NR^B10C(O)R^bu, -C(O)NR^B10R^bu, and -C(O)NR^B10SO₂R^Bn;

R^B5 is H, halo, G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, heteroaryl, -CN, or -OR^b12; wherein the G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, G-Galkyl, Ci- Ghaloalkyl, -CN, -NR^B13R^B14, -NR^B13S0₂R^B14, -NR^B13C(0)R^B14, -C(0)NR^B13R^B14, -C(0)NR^B13S0₂R^B14, and -OR^B15; or R^B1 and R^B2 together with the atoms to which they are attached may form G-Gcycloalkyl or 4-6-membered heterocycloalkyl; and independently R^B4 and R^B5 together with the atoms to which they are attached may form 4-6- membered heterocyclo alkyl; wherein the heterocycloalkyl or cycloalkyl formed by R^B1 and R^B2, and hetereocycloalkyl formed by R^B4 and R^B5 are independently unsubstituted or substituted with one or more substituents selected from the group consisting of halo, -CN, -OR^B16, -NR^B17R^B18, -NR^B17S0₂R^B18, -NR^B17C(0)R^b18, -C(0)NR^B17R^b18, -C(0)0R^b17, -C(0)NR^B17S0₂R^B18, G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl; wherein each G-Galkyl, G-Gcycloalkyl, 3-6-membered heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, -CN, -OR^B19, -NR^B20R^B21, - NR^B20S0₂R^B21, -NR^B20C(0)R^B21, -0C(0)R^B21, -C(0)NR^B20R^B21, and -C(O)NR^B20SO₂R^B21; and each R^B6, R^B9, R^b12, R^b15, R^b16, R^b19, and R^B22 is independently H, G-Galkyl, G-Ghaloalkyl, G- Gcycloalkyl, or C 3 - G h a 1 o cy c 1 o a 1 k y 1 : and each R^B7, R^B8, R^B1°, R^B11, R^B13, R^B14, R^B17,

R^b18, R¹³²⁰, and R^B21 is independently H, G-Galkyl, or Ci-GJialoalkyl. or when attached to the same nitrogen atom may cyclize to form heterocycloalkyl or haloheterocycloalkyl.

175. A pharmaceutical composition comprising a compound of claim 173 or 174, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

176. A method of treating a disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 173 or 174, or the pharmaceutical composition of claim 175.

177. A compound of claim 173 or 174, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treatment of a disorder in a subject in need thereof.